JPH11503722A - 炎症の治療のための置換イソオキサゾール - Google Patents
炎症の治療のための置換イソオキサゾールInfo
- Publication number
- JPH11503722A JPH11503722A JP8525057A JP52505796A JPH11503722A JP H11503722 A JPH11503722 A JP H11503722A JP 8525057 A JP8525057 A JP 8525057A JP 52505796 A JP52505796 A JP 52505796A JP H11503722 A JPH11503722 A JP H11503722A
- Authority
- JP
- Japan
- Prior art keywords
- benzenesulfonamide
- phenyl
- methyl
- phenylisoxazol
- isoxazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 26
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title abstract description 29
- 150000002545 isoxazoles Chemical class 0.000 title description 11
- -1 cyano, carboxyl Chemical group 0.000 claims abstract description 423
- 150000001875 compounds Chemical class 0.000 claims abstract description 106
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 87
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims abstract description 69
- 150000003839 salts Chemical class 0.000 claims abstract description 46
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 42
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 37
- 125000003118 aryl group Chemical group 0.000 claims abstract description 37
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 36
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 34
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 33
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 25
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 20
- 125000004438 haloalkoxy group Chemical group 0.000 claims abstract description 20
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 19
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 17
- 125000004181 carboxyalkyl group Chemical group 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims abstract description 15
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims abstract description 14
- 125000004103 aminoalkyl group Chemical group 0.000 claims abstract description 14
- 150000004678 hydrides Chemical class 0.000 claims abstract description 14
- 125000001769 aryl amino group Chemical group 0.000 claims abstract description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 12
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 11
- 125000005280 halo alkyl sulfonyloxy group Chemical group 0.000 claims abstract description 10
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 131
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 118
- 238000000034 method Methods 0.000 claims description 78
- 239000002253 acid Substances 0.000 claims description 54
- 125000005843 halogen group Chemical group 0.000 claims description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 32
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 25
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 24
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 19
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 17
- 125000003282 alkyl amino group Chemical group 0.000 claims description 17
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 17
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 17
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 17
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 16
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 15
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 14
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 13
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 claims description 13
- 125000006001 difluoroethyl group Chemical group 0.000 claims description 13
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 13
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000006343 heptafluoro propyl group Chemical group 0.000 claims description 12
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 12
- 125000006003 dichloroethyl group Chemical group 0.000 claims description 11
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 11
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims description 11
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 9
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 9
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 8
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 8
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 7
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 6
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims description 6
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 6
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000005164 aryl thioalkyl group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 5
- 229940095102 methyl benzoate Drugs 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- XOOMWXNEYSORAW-UHFFFAOYSA-N 2-[5-phenyl-4-(4-sulfamoylphenyl)-1,2-oxazol-3-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC=CC=2)ON=C1CC(O)=O XOOMWXNEYSORAW-UHFFFAOYSA-N 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 claims description 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 4
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- MFWGLBXPMTYHIL-UHFFFAOYSA-N 2-[3-(3-fluoro-4-methoxyphenyl)-4-(4-methylsulfonylphenyl)-1,2-oxazol-5-yl]acetic acid Chemical compound C1=C(F)C(OC)=CC=C1C1=NOC(CC(O)=O)=C1C1=CC=C(S(C)(=O)=O)C=C1 MFWGLBXPMTYHIL-UHFFFAOYSA-N 0.000 claims description 3
- LLWOSCPRJRUVST-UHFFFAOYSA-N 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonic acid Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(O)(=O)=O)C=C1 LLWOSCPRJRUVST-UHFFFAOYSA-N 0.000 claims description 3
- 206010037660 Pyrexia Diseases 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- XTWDZRKMOSCWCQ-UHFFFAOYSA-N 3-[4-phenyl-5-(4-sulfamoylphenyl)-1,2-oxazol-3-yl]propanoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC=CC=2)C(CCC(O)=O)=NO1 XTWDZRKMOSCWCQ-UHFFFAOYSA-N 0.000 claims description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 2
- MVGCUMIODCRQIA-UHFFFAOYSA-N 4-[[3-phenyl-4-(4-sulfamoylphenyl)-1,2-oxazol-5-yl]methoxy]benzoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C(C(=NO1)C=2C=CC=CC=2)=C1COC1=CC=C(C(O)=O)C=C1 MVGCUMIODCRQIA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- APMIVVBYHLSFJD-UHFFFAOYSA-N 5-(difluoromethyl)-4-(4-methylsulfonylphenyl)-3-phenyl-1,2-oxazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C(F)F)ON=C1C1=CC=CC=C1 APMIVVBYHLSFJD-UHFFFAOYSA-N 0.000 claims description 2
- SQAWJNWBEQKHAS-UHFFFAOYSA-N 5-[5-phenyl-4-(4-sulfamoylphenyl)-1,2-oxazol-3-yl]pentanoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC=CC=2)ON=C1CCCCC(O)=O SQAWJNWBEQKHAS-UHFFFAOYSA-N 0.000 claims description 2
- MXWFMEXKXHCNAX-UHFFFAOYSA-N 6-[4-phenyl-5-(4-sulfamoylphenyl)-1,2-oxazol-3-yl]hexanoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC=CC=2)C(CCCCCC(O)=O)=NO1 MXWFMEXKXHCNAX-UHFFFAOYSA-N 0.000 claims description 2
- WLDHHLLEGBRUMH-UHFFFAOYSA-N 6-[5-phenyl-4-(4-sulfamoylphenyl)-1,2-oxazol-3-yl]hexanoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC=CC=2)ON=C1CCCCCC(O)=O WLDHHLLEGBRUMH-UHFFFAOYSA-N 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 4
- UJSFKTUZOASIPA-UHFFFAOYSA-N 4-[5-(hydroxymethyl)-3-phenyl-1,2-oxazol-4-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(CO)ON=C1C1=CC=CC=C1 UJSFKTUZOASIPA-UHFFFAOYSA-N 0.000 claims 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 2
- TUYBDDJAXMAMIZ-UHFFFAOYSA-N 2-[[3-phenyl-4-(4-sulfamoylphenyl)-1,2-oxazol-5-yl]methoxy]acetic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(COCC(O)=O)ON=C1C1=CC=CC=C1 TUYBDDJAXMAMIZ-UHFFFAOYSA-N 0.000 claims 1
- DJMMCRDJGABXGD-UHFFFAOYSA-N 3-ethyl-4-(4-methylsulfonylphenyl)-5-phenyl-1,2-oxazole Chemical compound CCC1=NOC(C=2C=CC=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 DJMMCRDJGABXGD-UHFFFAOYSA-N 0.000 claims 1
- JDLMGASWHWBAOA-UHFFFAOYSA-N 3-methyl-4-(4-methylsulfonylphenyl)-5-phenyl-1,2-oxazole Chemical compound CC1=NOC(C=2C=CC=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 JDLMGASWHWBAOA-UHFFFAOYSA-N 0.000 claims 1
- VPPSNSWUXPAMQN-UHFFFAOYSA-N 3-methyl-5-(4-methylsulfonylphenyl)-4-phenyl-1,2-oxazole Chemical compound CC1=NOC(C=2C=CC(=CC=2)S(C)(=O)=O)=C1C1=CC=CC=C1 VPPSNSWUXPAMQN-UHFFFAOYSA-N 0.000 claims 1
- RFHGTZVUSNLUGD-UHFFFAOYSA-N 4-(3-methyl-4-phenyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CC1=NOC(C=2C=CC(=CC=2)S(N)(=O)=O)=C1C1=CC=CC=C1 RFHGTZVUSNLUGD-UHFFFAOYSA-N 0.000 claims 1
- SMSOSOLCGZNKJS-UHFFFAOYSA-N 4-(3-methyl-5-phenyl-1,2-oxazol-4-yl)benzenesulfonamide Chemical compound CC1=NOC(C=2C=CC=CC=2)=C1C1=CC=C(S(N)(=O)=O)C=C1 SMSOSOLCGZNKJS-UHFFFAOYSA-N 0.000 claims 1
- GJQORTDPTCXHSL-UHFFFAOYSA-N 4-[5-(difluoromethyl)-3-(4-methoxyphenyl)-1,2-oxazol-4-yl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1C1=NOC(C(F)F)=C1C1=CC=C(S(N)(=O)=O)C=C1 GJQORTDPTCXHSL-UHFFFAOYSA-N 0.000 claims 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 360
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 234
- 239000000243 solution Substances 0.000 description 200
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 148
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 146
- 239000000203 mixture Substances 0.000 description 124
- 238000002360 preparation method Methods 0.000 description 124
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 114
- 239000007787 solid Substances 0.000 description 106
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 101
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 98
- 238000006243 chemical reaction Methods 0.000 description 94
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 84
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 75
- 238000000921 elemental analysis Methods 0.000 description 72
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 72
- 238000001819 mass spectrum Methods 0.000 description 60
- 238000005160 1H NMR spectroscopy Methods 0.000 description 51
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 41
- 239000012043 crude product Substances 0.000 description 41
- 238000010992 reflux Methods 0.000 description 41
- 239000003921 oil Substances 0.000 description 40
- 235000019198 oils Nutrition 0.000 description 40
- 238000003756 stirring Methods 0.000 description 40
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 239000012267 brine Substances 0.000 description 39
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 39
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 38
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 36
- 235000019441 ethanol Nutrition 0.000 description 35
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 34
- 150000002923 oximes Chemical class 0.000 description 34
- 229940124530 sulfonamide Drugs 0.000 description 34
- 238000001914 filtration Methods 0.000 description 32
- 239000000725 suspension Substances 0.000 description 32
- 239000000047 product Substances 0.000 description 31
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 30
- 229920006395 saturated elastomer Polymers 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 28
- 235000011054 acetic acid Nutrition 0.000 description 27
- PAPNRQCYSFBWDI-UHFFFAOYSA-N 2,5-Dimethyl-1H-pyrrole Chemical compound CC1=CC=C(C)N1 PAPNRQCYSFBWDI-UHFFFAOYSA-N 0.000 description 26
- 125000004432 carbon atom Chemical group C* 0.000 description 26
- 239000007864 aqueous solution Substances 0.000 description 25
- 238000001816 cooling Methods 0.000 description 25
- 239000012044 organic layer Substances 0.000 description 25
- 239000000284 extract Substances 0.000 description 24
- 239000000463 material Substances 0.000 description 24
- 238000005481 NMR spectroscopy Methods 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 23
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 22
- 150000003456 sulfonamides Chemical class 0.000 description 22
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 21
- 150000002576 ketones Chemical class 0.000 description 21
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 21
- 235000019341 magnesium sulphate Nutrition 0.000 description 21
- 229910052757 nitrogen Inorganic materials 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 20
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 20
- 239000010410 layer Substances 0.000 description 20
- 238000002844 melting Methods 0.000 description 19
- 230000008018 melting Effects 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 17
- 239000008346 aqueous phase Substances 0.000 description 16
- 239000012141 concentrate Substances 0.000 description 16
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 16
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 15
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 15
- 239000002244 precipitate Substances 0.000 description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 14
- 239000013078 crystal Substances 0.000 description 14
- 238000003818 flash chromatography Methods 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 14
- 239000000843 powder Substances 0.000 description 13
- 229940086542 triethylamine Drugs 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 12
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 11
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 11
- 239000005457 ice water Substances 0.000 description 11
- 229910052744 lithium Inorganic materials 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 238000001953 recrystallisation Methods 0.000 description 11
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 11
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 10
- 239000000908 ammonium hydroxide Substances 0.000 description 10
- 238000000354 decomposition reaction Methods 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 description 10
- 235000019260 propionic acid Nutrition 0.000 description 10
- 239000001632 sodium acetate Substances 0.000 description 10
- 235000017281 sodium acetate Nutrition 0.000 description 10
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 9
- 235000011089 carbon dioxide Nutrition 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 9
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 9
- 125000004430 oxygen atom Chemical group O* 0.000 description 9
- 239000000376 reactant Substances 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 125000004434 sulfur atom Chemical group 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000701447 unidentified baculovirus Species 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- OTKCEEWUXHVZQI-UHFFFAOYSA-N 1,2-diphenylethanone Chemical class C=1C=CC=CC=1C(=O)CC1=CC=CC=C1 OTKCEEWUXHVZQI-UHFFFAOYSA-N 0.000 description 8
- 238000004293 19F NMR spectroscopy Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229940121363 anti-inflammatory agent Drugs 0.000 description 8
- 239000002260 anti-inflammatory agent Substances 0.000 description 8
- 235000010418 carrageenan Nutrition 0.000 description 8
- 229920001525 carrageenan Polymers 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 7
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000011630 iodine Substances 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000003828 vacuum filtration Methods 0.000 description 7
- GKDLTXYXODKDEA-UHFFFAOYSA-N 1-phenylbutan-2-one Chemical compound CCC(=O)CC1=CC=CC=C1 GKDLTXYXODKDEA-UHFFFAOYSA-N 0.000 description 6
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 6
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 6
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 6
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 150000003857 carboxamides Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 125000004475 heteroaralkyl group Chemical group 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- KEVAZWIBJQZOHC-UHFFFAOYSA-N 4-phenyl-1,2-oxazole Chemical compound C1=NOC=C1C1=CC=CC=C1 KEVAZWIBJQZOHC-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000000679 carrageenan Substances 0.000 description 5
- 229940113118 carrageenan Drugs 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 5
- QCCDLTOVEPVEJK-UHFFFAOYSA-N phenylacetone Chemical compound CC(=O)CC1=CC=CC=C1 QCCDLTOVEPVEJK-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- SDCZGTFGVWHUDH-UHFFFAOYSA-N 1,2-diphenylpent-1-en-3-one Chemical compound C=1C=CC=CC=1C(C(=O)CC)=CC1=CC=CC=C1 SDCZGTFGVWHUDH-UHFFFAOYSA-N 0.000 description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 4
- 125000004864 4-thiomethylphenyl group Chemical group 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001024304 Mino Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- GZKHDVAKKLTJPO-UHFFFAOYSA-N ethyl 2,2-difluoroacetate Chemical compound CCOC(=O)C(F)F GZKHDVAKKLTJPO-UHFFFAOYSA-N 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 239000000052 vinegar Substances 0.000 description 4
- 235000021419 vinegar Nutrition 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 3
- OARWXDXELDVNOC-UHFFFAOYSA-N 2-(3-chloro-4-methoxyphenyl)acetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1Cl OARWXDXELDVNOC-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- MIIAJVAHNFTLCE-UHFFFAOYSA-N CCCC1=NOC(=C1C2=CC=CC=C2)C3=CC=CC=C3 Chemical class CCCC1=NOC(=C1C2=CC=CC=C2)C3=CC=CC=C3 MIIAJVAHNFTLCE-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000234435 Lilium Species 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 230000002051 biphasic effect Effects 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 208000006278 hypochromic anemia Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZEYYDOLCHFETHQ-JOCHJYFZSA-N (2r)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Chemical compound C1([C@@H](C(=O)O)C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)CCCC1 ZEYYDOLCHFETHQ-JOCHJYFZSA-N 0.000 description 2
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 2
- BUMMZWFWCNQFPS-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[5-(4-carbamimidoylphenoxy)pentoxy]-3-methoxy-n,n-di(propan-2-yl)benzamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 BUMMZWFWCNQFPS-BTJKTKAUSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ZHLKECGIYFTWEZ-UHFFFAOYSA-N 1-(3-chloro-4-methoxyphenyl)-2-(4-methylsulfanylphenyl)ethanone Chemical compound C1=C(Cl)C(OC)=CC=C1C(=O)CC1=CC=C(SC)C=C1 ZHLKECGIYFTWEZ-UHFFFAOYSA-N 0.000 description 2
- PLALKSRAHVYFOH-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-phenylethanone Chemical compound C1=CC(OC)=CC=C1C(=O)CC1=CC=CC=C1 PLALKSRAHVYFOH-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- JIXDOBAQOWOUPA-UHFFFAOYSA-N 1-fluoro-2-methoxybenzene Chemical compound COC1=CC=CC=C1F JIXDOBAQOWOUPA-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JLIDVCMBCGBIEY-UHFFFAOYSA-N 1-penten-3-one Chemical compound CCC(=O)C=C JLIDVCMBCGBIEY-UHFFFAOYSA-N 0.000 description 2
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 description 2
- OJVAMHKKJGICOG-UHFFFAOYSA-N 2,5-hexanedione Chemical compound CC(=O)CCC(C)=O OJVAMHKKJGICOG-UHFFFAOYSA-N 0.000 description 2
- NSTGHVBQWUEIAG-UHFFFAOYSA-N 2-(3,4-diphenyl-1,2-oxazol-5-yl)acetic acid Chemical compound OC(=O)CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 NSTGHVBQWUEIAG-UHFFFAOYSA-N 0.000 description 2
- AHMLFHMRRBJCRM-UHFFFAOYSA-N 2-(4-methylsulfanylphenyl)acetic acid Chemical compound CSC1=CC=C(CC(O)=O)C=C1 AHMLFHMRRBJCRM-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- JKLWRNPSXPFPNN-UHFFFAOYSA-N 2-[3-phenyl-4-(4-sulfamoylphenyl)-1,2-oxazol-5-yl]propanoic acid Chemical compound OC(=O)C(C)C=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 JKLWRNPSXPFPNN-UHFFFAOYSA-N 0.000 description 2
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- WZVWGMPHAQTGPO-UHFFFAOYSA-N 3,4-diphenyl-4h-1,2-oxazol-5-one Chemical compound O=C1ON=C(C=2C=CC=CC=2)C1C1=CC=CC=C1 WZVWGMPHAQTGPO-UHFFFAOYSA-N 0.000 description 2
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- CCMXNCFGZLATQH-UHFFFAOYSA-N 4-(3-chlorophenyl)-3-phenylbut-3-en-2-one Chemical compound C=1C=CC=CC=1C(C(=O)C)=CC1=CC=CC(Cl)=C1 CCMXNCFGZLATQH-UHFFFAOYSA-N 0.000 description 2
- OHUPHNWMLWIYGY-UHFFFAOYSA-N 4-(4-chlorophenyl)-3-phenylbut-3-en-2-one Chemical compound C=1C=CC=CC=1C(C(=O)C)=CC1=CC=C(Cl)C=C1 OHUPHNWMLWIYGY-UHFFFAOYSA-N 0.000 description 2
- AOXHNERUPRMRLB-UHFFFAOYSA-N 4-(4-fluorophenyl)-3-phenylbut-3-en-2-one Chemical compound C=1C=CC=CC=1C(C(=O)C)=CC1=CC=C(F)C=C1 AOXHNERUPRMRLB-UHFFFAOYSA-N 0.000 description 2
- YKGHXLZCTDGDEJ-UHFFFAOYSA-N 4-(4-methylphenyl)-3-phenylbut-3-en-2-one Chemical compound C=1C=CC=CC=1C(C(=O)C)=CC1=CC=C(C)C=C1 YKGHXLZCTDGDEJ-UHFFFAOYSA-N 0.000 description 2
- VARNELXEPYTJEG-UHFFFAOYSA-N 4-(5-oxo-3-phenyl-2h-1,2-oxazol-4-yl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC=CC=2)NOC1=O VARNELXEPYTJEG-UHFFFAOYSA-N 0.000 description 2
- ZLPCRPIDSXHGTO-UHFFFAOYSA-N 4-[5-(difluoromethyl)-3-(3-fluoro-4-methoxyphenyl)-1,2-oxazol-4-yl]benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1C1=NOC(C(F)F)=C1C1=CC=C(S(N)(=O)=O)C=C1 ZLPCRPIDSXHGTO-UHFFFAOYSA-N 0.000 description 2
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
- ZXIRUKJWLADSJS-UHFFFAOYSA-N 5-methyl-3,4-diphenyl-1,2-oxazole Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 ZXIRUKJWLADSJS-UHFFFAOYSA-N 0.000 description 2
- AIWQSOFGFNKOOF-UHFFFAOYSA-N 5-methyl-4-(4-methylsulfonylphenyl)-3-phenyl-1,2-oxazole Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(C)(=O)=O)C=C1 AIWQSOFGFNKOOF-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CRZQGDNQQAALAY-UHFFFAOYSA-N Methyl benzeneacetate Chemical compound COC(=O)CC1=CC=CC=C1 CRZQGDNQQAALAY-UHFFFAOYSA-N 0.000 description 2
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 239000012425 OXONE® Substances 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- LUOUCHOLMUUZBO-SVSXJNCISA-N [4-[(1e,3e)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate Chemical compound C1=C(OC)C(OC(=O)OCC)=CC=C1\C=C\C=C\C(=O)NCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 LUOUCHOLMUUZBO-SVSXJNCISA-N 0.000 description 2
- FZENGILVLUJGJX-UHFFFAOYSA-N acetaldehyde oxime Chemical compound CC=NO FZENGILVLUJGJX-UHFFFAOYSA-N 0.000 description 2
- 229940008309 acetone / ethanol Drugs 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 150000007962 benzene acetonitriles Chemical class 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- GTBRTGPZZALPNS-MXHVRSFHSA-N cyanoketone Chemical compound C1C=C2C(C)(C)C(=O)[C@H](C#N)C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GTBRTGPZZALPNS-MXHVRSFHSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 125000004982 dihaloalkyl group Chemical group 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229950010033 ebselen Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- WARQUFORVQESFF-UHFFFAOYSA-N isocyanatoethene Chemical compound C=CN=C=O WARQUFORVQESFF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 125000006682 monohaloalkyl group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- SUSQOBVLVYHIEX-UHFFFAOYSA-N o-phenylene-diaceto-nitrile Natural products N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 125000006684 polyhaloalkyl group Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- GKDIMGQSBSDJNC-UHFFFAOYSA-M sodium;2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoate Chemical compound [Na+].C1=CC=C(OC=2C(=CC=CC=2)C([O-])=O)C(CCC)=C1OCCCOC(C(=C1)CC)=CC(O)=C1C1=CC=C(F)C=C1 GKDIMGQSBSDJNC-UHFFFAOYSA-M 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 2
- 125000000565 sulfonamide group Chemical group 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 2
- 229960003676 tenidap Drugs 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical class [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 1
- XKKGMVDIONCFKP-UHFFFAOYSA-N (2-butyl-4-methoxynaphthalen-1-yl) acetate Chemical compound C1=CC=CC2=C(OC(C)=O)C(CCCC)=CC(OC)=C21 XKKGMVDIONCFKP-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CVKWNJFUPVHKFY-MDZDMXLPSA-N (e)-1-(4-chlorophenyl)-3-(3-methylanilino)prop-2-en-1-one Chemical compound CC1=CC=CC(N\C=C\C(=O)C=2C=CC(Cl)=CC=2)=C1 CVKWNJFUPVHKFY-MDZDMXLPSA-N 0.000 description 1
- PWCUVRROUAKTLL-PFONDFGASA-N (nz)-n-(1,2-diphenylethylidene)hydroxylamine Chemical compound C=1C=CC=CC=1C(=N/O)\CC1=CC=CC=C1 PWCUVRROUAKTLL-PFONDFGASA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- LOXSIFYRCPLYMU-UHFFFAOYSA-N 1,2-diphenylpent-1-en-3-one hydrobromide Chemical compound Br.C1(=CC=CC=C1)C=C(C(CC)=O)C1=CC=CC=C1 LOXSIFYRCPLYMU-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- PIYNUZCGMLCXKJ-UHFFFAOYSA-N 1,4-dioxane-2,6-dione Chemical compound O=C1COCC(=O)O1 PIYNUZCGMLCXKJ-UHFFFAOYSA-N 0.000 description 1
- ZAKNRBRFLQSIBK-UHFFFAOYSA-N 1-(2-fluorophenyl)-2-phenylethanone Chemical compound FC1=CC=CC=C1C(=O)CC1=CC=CC=C1 ZAKNRBRFLQSIBK-UHFFFAOYSA-N 0.000 description 1
- QILWOKAXHOAFOF-UHFFFAOYSA-N 1-(3-chloro-4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(C)=O)C=C1Cl QILWOKAXHOAFOF-UHFFFAOYSA-N 0.000 description 1
- IWDLWRYPZHYWLN-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-phenylethanone Chemical compound ClC1=CC=CC(C(=O)CC=2C=CC=CC=2)=C1 IWDLWRYPZHYWLN-UHFFFAOYSA-N 0.000 description 1
- MOSIKPSTRPODHQ-UHFFFAOYSA-N 1-(4-bromophenyl)-2-phenylethan-1-one Chemical compound C1=CC(Br)=CC=C1C(=O)CC1=CC=CC=C1 MOSIKPSTRPODHQ-UHFFFAOYSA-N 0.000 description 1
- RDBAEHHVVNBKBB-UHFFFAOYSA-N 1-(4-methylphenyl)-2-phenylethanone Chemical compound C1=CC(C)=CC=C1C(=O)CC1=CC=CC=C1 RDBAEHHVVNBKBB-UHFFFAOYSA-N 0.000 description 1
- ZGWJWTIJZNHZKE-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)butan-2-one Chemical compound CCC(=O)CC1=CC=C(SC)C=C1 ZGWJWTIJZNHZKE-UHFFFAOYSA-N 0.000 description 1
- RYFZDEIJXAESAA-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)propan-2-one Chemical compound CSC1=CC=C(CC(C)=O)C=C1 RYFZDEIJXAESAA-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- QGRPVMLBTFGQDQ-UHFFFAOYSA-N 1-chloro-2-methoxybenzene Chemical compound COC1=CC=CC=C1Cl QGRPVMLBTFGQDQ-UHFFFAOYSA-N 0.000 description 1
- KIQQUVJOLVCZKG-UHFFFAOYSA-N 1-chloro-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(Cl)C=C1 KIQQUVJOLVCZKG-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- PFNKRICCWLHZFV-UHFFFAOYSA-N 2-(1,2-oxazol-3-yl)phenol Chemical compound OC1=CC=CC=C1C1=NOC=C1 PFNKRICCWLHZFV-UHFFFAOYSA-N 0.000 description 1
- ZOJJJVRLKLQJNV-UHFFFAOYSA-N 2-(2,2-dimethoxyethoxy)-1,1-dimethoxyethane Chemical compound COC(OC)COCC(OC)OC ZOJJJVRLKLQJNV-UHFFFAOYSA-N 0.000 description 1
- QAXYIXUGMPQCJN-UHFFFAOYSA-N 2-(3,4-diphenyl-1,2-oxazol-5-yl)propanoic acid Chemical compound OC(=O)C(C)C=1ON=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 QAXYIXUGMPQCJN-UHFFFAOYSA-N 0.000 description 1
- UIJWMSUSZQORDJ-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 UIJWMSUSZQORDJ-UHFFFAOYSA-N 0.000 description 1
- TZNHIWAKRVUVEB-UHFFFAOYSA-N 2-(4-methylsulfanylphenyl)-1-phenylethanone Chemical compound C1=CC(SC)=CC=C1CC(=O)C1=CC=CC=C1 TZNHIWAKRVUVEB-UHFFFAOYSA-N 0.000 description 1
- HXMUFUQHIXAJSS-UHFFFAOYSA-N 2-(4-methylsulfanylphenyl)-1-phenylpent-1-en-3-one Chemical compound C=1C=C(SC)C=CC=1C(C(=O)CC)=CC1=CC=CC=C1 HXMUFUQHIXAJSS-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical class CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- AVEBTBGTXHWMKK-UHFFFAOYSA-N 2-[3-(3-fluoro-4-methoxyphenyl)-4-(4-sulfamoylphenyl)-1,2-oxazol-5-yl]propanoic acid Chemical compound C1=C(F)C(OC)=CC=C1C1=NOC(C(C)C(O)=O)=C1C1=CC=C(S(N)(=O)=O)C=C1 AVEBTBGTXHWMKK-UHFFFAOYSA-N 0.000 description 1
- AQKFDFRMIGWSJH-UHFFFAOYSA-N 2-[3-phenyl-4-(4-sulfamoylphenyl)-1,2-oxazol-5-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(CC(O)=O)ON=C1C1=CC=CC=C1 AQKFDFRMIGWSJH-UHFFFAOYSA-N 0.000 description 1
- GIPMRBOAEXOWKG-UHFFFAOYSA-N 2-[4-(4-methylsulfanylphenyl)-3-phenyl-1,2-oxazol-5-yl]acetic acid Chemical compound C1=CC(SC)=CC=C1C1=C(CC(O)=O)ON=C1C1=CC=CC=C1 GIPMRBOAEXOWKG-UHFFFAOYSA-N 0.000 description 1
- JJYLLRFGABRJMB-UHFFFAOYSA-N 2-[4-(4-methylsulfonylphenyl)-3-phenyl-1,2-oxazol-5-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(CC(O)=O)ON=C1C1=CC=CC=C1 JJYLLRFGABRJMB-UHFFFAOYSA-N 0.000 description 1
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- ASOFZHSTJHGQDT-UHFFFAOYSA-N 3,5-difluorobenzaldehyde Chemical compound FC1=CC(F)=CC(C=O)=C1 ASOFZHSTJHGQDT-UHFFFAOYSA-N 0.000 description 1
- LCVXGTMXKBWJES-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-5-methyl-4-(4-methylsulfonylphenyl)-1,2-oxazole Chemical compound CC=1ON=C(C=2C=C(Cl)C(Cl)=CC=2)C=1C1=CC=C(S(C)(=O)=O)C=C1 LCVXGTMXKBWJES-UHFFFAOYSA-N 0.000 description 1
- FULDVXVENHBJAM-UHFFFAOYSA-N 3-(3,5-difluoro-4-methoxyphenyl)-5-methyl-4-(4-methylsulfonylphenyl)-1,2-oxazole Chemical compound C1=C(F)C(OC)=C(F)C=C1C1=NOC(C)=C1C1=CC=C(S(C)(=O)=O)C=C1 FULDVXVENHBJAM-UHFFFAOYSA-N 0.000 description 1
- YMPDTNVWTZTASE-UHFFFAOYSA-N 3-(3-fluoro-4-methoxyphenyl)-5-methyl-4-(4-methylsulfanylphenyl)-1,2-oxazole Chemical compound C1=C(F)C(OC)=CC=C1C1=NOC(C)=C1C1=CC=C(SC)C=C1 YMPDTNVWTZTASE-UHFFFAOYSA-N 0.000 description 1
- KYNUIPXAPRCCIV-UHFFFAOYSA-N 3-(3-fluoro-4-methoxyphenyl)-5-methyl-4-phenyl-4h-1,2-oxazol-5-ol Chemical compound C1=C(F)C(OC)=CC=C1C1=NOC(C)(O)C1C1=CC=CC=C1 KYNUIPXAPRCCIV-UHFFFAOYSA-N 0.000 description 1
- OTGYRRGOZRCIPW-UHFFFAOYSA-N 3-(4-bromophenyl)-5-methyl-4-phenyl-1,2-oxazole Chemical compound CC=1ON=C(C=2C=CC(Br)=CC=2)C=1C1=CC=CC=C1 OTGYRRGOZRCIPW-UHFFFAOYSA-N 0.000 description 1
- CLQWJETXSQUENY-UHFFFAOYSA-N 3-(4-chlorophenyl)-5-methyl-4-(4-methylsulfonylphenyl)-1,2-oxazole Chemical compound CC=1ON=C(C=2C=CC(Cl)=CC=2)C=1C1=CC=C(S(C)(=O)=O)C=C1 CLQWJETXSQUENY-UHFFFAOYSA-N 0.000 description 1
- AHBHKZCSIUIANZ-UHFFFAOYSA-N 3-(4-methylsulfanylphenyl)prop-2-enoic acid Chemical compound CSC1=CC=C(C=CC(O)=O)C=C1 AHBHKZCSIUIANZ-UHFFFAOYSA-N 0.000 description 1
- YWYUQSGYKDEAMJ-QFIPXVFZSA-N 3-[(2s)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2h-chromen-2-yl]propanoic acid Chemical compound O([C@H](CCC(O)=O)CCC=1C=C2)C=1C(CCC)=C2OCCCOC1=CC=C(C(=O)NC)C(OC)=C1CC1CC1 YWYUQSGYKDEAMJ-QFIPXVFZSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- RAGDIUOHVSSYCS-UHFFFAOYSA-N 3-[5-phenyl-4-(4-sulfamoylphenyl)-1,2-oxazol-3-yl]propanoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC=CC=2)ON=C1CCC(O)=O RAGDIUOHVSSYCS-UHFFFAOYSA-N 0.000 description 1
- YWYUQSGYKDEAMJ-UHFFFAOYSA-N 3-[7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2h-chromen-2-yl]propanoic acid Chemical compound C1=CC=2CCC(CCC(O)=O)OC=2C(CCC)=C1OCCCOC1=CC=C(C(=O)NC)C(OC)=C1CC1CC1 YWYUQSGYKDEAMJ-UHFFFAOYSA-N 0.000 description 1
- LXISYGKVOTXHAQ-UHFFFAOYSA-N 3-ethyl-4,5-diphenyl-1,2-oxazole Chemical compound CCC1=NOC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 LXISYGKVOTXHAQ-UHFFFAOYSA-N 0.000 description 1
- YQLVIOYSGHEJDA-UHFFFAOYSA-N 3-methyloxane-2,6-dione Chemical compound CC1CCC(=O)OC1=O YQLVIOYSGHEJDA-UHFFFAOYSA-N 0.000 description 1
- ZBRDJMFLJXFIGJ-UHFFFAOYSA-N 3-phenyl-1,2-oxazole Chemical compound O1C=CC(C=2C=CC=CC=2)=N1 ZBRDJMFLJXFIGJ-UHFFFAOYSA-N 0.000 description 1
- JQUNIZHXEAOQQR-UHFFFAOYSA-N 3-phenyl-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2C=CC=CC=2)=N1 JQUNIZHXEAOQQR-UHFFFAOYSA-N 0.000 description 1
- JJZNCUHIYJBAMS-UHFFFAOYSA-N 3-phenyl-2h-1,2-oxazol-5-one Chemical compound N1OC(=O)C=C1C1=CC=CC=C1 JJZNCUHIYJBAMS-UHFFFAOYSA-N 0.000 description 1
- AEAVMNLZENBJSN-UHFFFAOYSA-N 3-phenyl-4-(4-sulfamoylphenyl)-1,2-oxazole-5-carboxylic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C(O)=O)ON=C1C1=CC=CC=C1 AEAVMNLZENBJSN-UHFFFAOYSA-N 0.000 description 1
- BPQAYMFGBGMJRY-UHFFFAOYSA-N 4,6-dimethyl-2-(6-phenylhexylamino)pyrimidin-5-ol;phosphoric acid Chemical compound OP(O)(O)=O.CC1=C(O)C(C)=NC(NCCCCCCC=2C=CC=CC=2)=N1 BPQAYMFGBGMJRY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HQFSNUYUXXPVKL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CCC1 HQFSNUYUXXPVKL-UHFFFAOYSA-N 0.000 description 1
- MIWGTEDDCFJPDK-UHFFFAOYSA-N 4-[3-(4-bromophenyl)-5-methyl-1,2-oxazol-4-yl]benzenesulfonamide Chemical compound CC=1ON=C(C=2C=CC(Br)=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 MIWGTEDDCFJPDK-UHFFFAOYSA-N 0.000 description 1
- FAVNKKAMPRFSMI-UHFFFAOYSA-N 4-[4-phenyl-5-(4-sulfamoylphenyl)-1,2-oxazol-3-yl]butanoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC=CC=2)C(CCCC(O)=O)=NO1 FAVNKKAMPRFSMI-UHFFFAOYSA-N 0.000 description 1
- NCGQJUCLGIDBMX-UHFFFAOYSA-N 4-[5-phenyl-4-(4-sulfamoylphenyl)-1,2-oxazol-3-yl]butanoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC=CC=2)ON=C1CCCC(O)=O NCGQJUCLGIDBMX-UHFFFAOYSA-N 0.000 description 1
- KRCUWCAUDKTMPB-UHFFFAOYSA-N 4-[[n-[(3-fluorophenyl)methyl]-4-(quinolin-2-ylmethoxy)anilino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN(C=1C=CC(OCC=2N=C3C=CC=CC3=CC=2)=CC=1)CC1=CC=CC(F)=C1 KRCUWCAUDKTMPB-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- PIMQQGJMDMAZGT-UHFFFAOYSA-N 4-methylthiobenzaldehyde Chemical compound CC1=CC=C(C=S)C=C1 PIMQQGJMDMAZGT-UHFFFAOYSA-N 0.000 description 1
- ADDQDQRGILNXTJ-UHFFFAOYSA-N 4-phenacylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CC(=O)C1=CC=CC=C1 ADDQDQRGILNXTJ-UHFFFAOYSA-N 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- JOPSSWGWLCLPPF-RUDMXATFSA-N 5-[2-(2-carboxyethyl)-3-[(e)-6-(4-methoxyphenyl)hex-5-enoxy]phenoxy]pentanoic acid Chemical compound C1=CC(OC)=CC=C1\C=C\CCCCOC1=CC=CC(OCCCCC(O)=O)=C1CCC(O)=O JOPSSWGWLCLPPF-RUDMXATFSA-N 0.000 description 1
- JOPSSWGWLCLPPF-UHFFFAOYSA-N 5-[2-(2-carboxyethyl)-3-[6-(4-methoxyphenyl)hex-5-enoxy]phenoxy]pentanoic acid Chemical compound C1=CC(OC)=CC=C1C=CCCCCOC1=CC=CC(OCCCCC(O)=O)=C1CCC(O)=O JOPSSWGWLCLPPF-UHFFFAOYSA-N 0.000 description 1
- UBMCVYGWJWGKRF-UHFFFAOYSA-N 5-[4-phenyl-5-(4-sulfamoylphenyl)-1,2-oxazol-3-yl]pentanoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC=CC=2)C(CCCCC(O)=O)=NO1 UBMCVYGWJWGKRF-UHFFFAOYSA-N 0.000 description 1
- SYLRRFCSVYKXIW-UHFFFAOYSA-N 5-methyl-3-(4-methylphenyl)-4-(4-methylsulfonylphenyl)-1,2-oxazole Chemical compound CC=1ON=C(C=2C=CC(C)=CC=2)C=1C1=CC=C(S(C)(=O)=O)C=C1 SYLRRFCSVYKXIW-UHFFFAOYSA-N 0.000 description 1
- UCGIIOJWRLQBRP-UHFFFAOYSA-N 5-methyl-3-phenyl-1,2-oxazole Chemical compound O1C(C)=CC(C=2C=CC=CC=2)=N1 UCGIIOJWRLQBRP-UHFFFAOYSA-N 0.000 description 1
- ZVVCSBSDFGYRCB-UHFFFAOYSA-N 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound C1=CC(C(C)=O)=C(OC)C(CCC)=C1OCCCOC1=CC=C(CCC(O2)C(O)=O)C2=C1CCC ZVVCSBSDFGYRCB-UHFFFAOYSA-N 0.000 description 1
- NFHKAMAWIQHXAT-UHFFFAOYSA-N 7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(1,3-thiazol-4-yl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound C1=CC=2CCC(C(O)=O)OC=2C(CCC)=C1OCCCOC(C(=C1OC)CC2CC2)=CC=C1C1=CSC=N1 NFHKAMAWIQHXAT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- CYEYGNQMWANENI-UHFFFAOYSA-N BrC1=CC=C(C=O)C=C1.BrC1=CC=C(C=C1)C(CC1=CC=CC=C1)=O Chemical compound BrC1=CC=C(C=O)C=C1.BrC1=CC=C(C=C1)C(CC1=CC=CC=C1)=O CYEYGNQMWANENI-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000197192 Bulla gouldiana Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- OSTRXSMSQMLVKI-UHFFFAOYSA-N C(#N)[Si](C)(C)C.ClC=1C=C(C=CC1)C(CC1=CC=CC=C1)=O Chemical compound C(#N)[Si](C)(C)C.ClC=1C=C(C=CC1)C(CC1=CC=CC=C1)=O OSTRXSMSQMLVKI-UHFFFAOYSA-N 0.000 description 1
- XMMBWGOZMVXHTL-UHFFFAOYSA-N C1(=CC=CC=C1)CC(=O)O.C1(=CC=CC=C1)C(C(=O)O)=C Chemical compound C1(=CC=CC=C1)CC(=O)O.C1(=CC=CC=C1)C(C(=O)O)=C XMMBWGOZMVXHTL-UHFFFAOYSA-N 0.000 description 1
- FBAGAKKRBXELMP-UHFFFAOYSA-N C=1C=CC=CC=1C(C(=NO)CC)=CC1=CC=CC=C1 Chemical compound C=1C=CC=CC=1C(C(=NO)CC)=CC1=CC=CC=C1 FBAGAKKRBXELMP-UHFFFAOYSA-N 0.000 description 1
- MIEFVQIJSAGPBZ-UHFFFAOYSA-N CCC[Mg] Chemical compound CCC[Mg] MIEFVQIJSAGPBZ-UHFFFAOYSA-N 0.000 description 1
- CMWRRNNWGUKSLI-UHFFFAOYSA-N COC(=O)C1=CC=C(O)C=C1.COC(C1=CC=CC=C1)=O Chemical compound COC(=O)C1=CC=C(O)C=C1.COC(C1=CC=CC=C1)=O CMWRRNNWGUKSLI-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- SBUKLPSBNFWJCU-UHFFFAOYSA-N ClIBr Chemical compound ClIBr SBUKLPSBNFWJCU-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 235000013175 Crataegus laevigata Nutrition 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YVECGMZCTULTIS-HSUXUTPPSA-N D-galactal Chemical compound OC[C@H]1OC=C[C@@H](O)[C@H]1O YVECGMZCTULTIS-HSUXUTPPSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004799 Geofoam Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
- 101000605121 Mus musculus Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 101000605126 Mus musculus Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 101001135788 Pinus taeda (+)-alpha-pinene synthase, chloroplastic Proteins 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000006778 Pummerer Sulfoxide rearrangement reaction Methods 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCIDNIHEOHAIAB-IBRXEVPMSA-N [(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S,5R)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] 2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]acetate Chemical compound CC(C)(C)OC(NCC(NCC(O[C@@H](CC1)C(C)(C)[C@H](CC2)[C@@]1(C)[C@@H](C1)[C@]2(C)[C@](C)(CC[C@@H]2[C@](C)(CC3)O[C@H]3C(C)(C)O)[C@@H]2[C@@H]1O)=O)=O)=O QCIDNIHEOHAIAB-IBRXEVPMSA-N 0.000 description 1
- WRTUXHMPXJGXDS-UHFFFAOYSA-N [4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylcarbamic acid Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(=O)(=O)NC(O)=O)C=C1 WRTUXHMPXJGXDS-UHFFFAOYSA-N 0.000 description 1
- XOHPWQWDGCMYHQ-UHFFFAOYSA-M [Br-].C(CCC)[Mg+].C1(=CC=CC=C1)CC(CCCC)=O Chemical compound [Br-].C(CCC)[Mg+].C1(=CC=CC=C1)CC(CCCC)=O XOHPWQWDGCMYHQ-UHFFFAOYSA-M 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- SWLWKUBAKZNVAR-UHFFFAOYSA-N [O-2].[Mg+2].[Na+] Chemical compound [O-2].[Mg+2].[Na+] SWLWKUBAKZNVAR-UHFFFAOYSA-N 0.000 description 1
- FABFZWSLYMVOHB-UHFFFAOYSA-M [OH-].[K+].C1(=CC=CC=C1)C=C(C(CC)=NO)C1=CC=CC=C1 Chemical compound [OH-].[K+].C1(=CC=CC=C1)C=C(C(CC)=NO)C1=CC=CC=C1 FABFZWSLYMVOHB-UHFFFAOYSA-M 0.000 description 1
- JOQYQKNTEBBQEZ-UHFFFAOYSA-I [Th+4].C(C)(=O)[O-].[Na+].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-] Chemical compound [Th+4].C(C)(=O)[O-].[Na+].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-] JOQYQKNTEBBQEZ-UHFFFAOYSA-I 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- WRVRNZNDLRUXSW-UHFFFAOYSA-N acetic acid;prop-2-enoic acid Chemical compound CC(O)=O.OC(=O)C=C WRVRNZNDLRUXSW-UHFFFAOYSA-N 0.000 description 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005081 alkoxyalkoxyalkyl group Chemical group 0.000 description 1
- 125000006550 alkoxycarbonyl aryl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000005094 alkyl carbonyl amino alkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- CWNKMHIETKEBCA-UHFFFAOYSA-N alpha-Ethylaminohexanophenone Chemical compound CCCCC(NCC)C(=O)C1=CC=CC=C1 CWNKMHIETKEBCA-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- AADWPQVILYBLPV-UHFFFAOYSA-N benzene 1-(4-bromophenyl)-2-phenylethanone Chemical compound C1=CC=CC=C1.BrC1=CC=C(C=C1)C(=O)CC1=CC=CC=C1 AADWPQVILYBLPV-UHFFFAOYSA-N 0.000 description 1
- IRYKNACNDZIGFV-UHFFFAOYSA-N benzenesulfonamide sulfurochloridic acid Chemical compound ClS(=O)(=O)O.C1(=CC=CC=C1)S(=O)(=O)N IRYKNACNDZIGFV-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 229950006427 bunaprolast Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- UUPSCULOIIVHCB-UHFFFAOYSA-N chembl1555398 Chemical class OC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 UUPSCULOIIVHCB-UHFFFAOYSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 125000004651 chloromethoxy group Chemical group ClCO* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- DXGPLGPVXNBIQZ-UHFFFAOYSA-L copper;2-hydroxybenzoate;methyl n-(1h-benzimidazol-2-yl)carbamate;6-methyl-n-phenyl-2,3-dihydro-1,4-oxathiine-5-carboxamide;quinolin-8-olate Chemical compound [Cu+2].OC1=CC=CC=C1C([O-])=O.C1=CN=C2C([O-])=CC=CC2=C1.C1=CC=C2NC(NC(=O)OC)=NC2=C1.S1CCOC(C)=C1C(=O)NC1=CC=CC=C1 DXGPLGPVXNBIQZ-UHFFFAOYSA-L 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- PBGGNZZGJIKBMJ-UHFFFAOYSA-N di(propan-2-yl)azanide Chemical compound CC(C)[N-]C(C)C PBGGNZZGJIKBMJ-UHFFFAOYSA-N 0.000 description 1
- 125000004983 dialkoxyalkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950006000 flezelastine Drugs 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- VZNYXGQMDSRJAL-UHFFFAOYSA-N iodomethyl(trimethyl)silane Chemical compound C[Si](C)(C)CI VZNYXGQMDSRJAL-UHFFFAOYSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004286 isoxazolin-3-yl group Chemical group [H]C1([H])ON=C(*)C1([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 150000002641 lithium Chemical class 0.000 description 1
- GAKBAJRHMOZPAU-UHFFFAOYSA-L lithium sodium diacetate Chemical compound [Na+].CC([O-])=O.[Li]OC(C)=O GAKBAJRHMOZPAU-UHFFFAOYSA-L 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- UQGNSVPCBCFZCE-UHFFFAOYSA-N methyl 4-methylsulfanylbenzoate Chemical compound COC(=O)C1=CC=C(SC)C=C1 UQGNSVPCBCFZCE-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- HWWVAHCWJLGKLW-UHFFFAOYSA-N n,n-dimethylhydroxylamine;hydron;chloride Chemical compound Cl.CN(C)O HWWVAHCWJLGKLW-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- JHNRZXQVBKRYKN-UHFFFAOYSA-N n-(1-phenylethylidene)hydroxylamine Chemical compound ON=C(C)C1=CC=CC=C1 JHNRZXQVBKRYKN-UHFFFAOYSA-N 0.000 description 1
- ULQNIOVTGLPBKJ-UHFFFAOYSA-N n-[1-(3-fluoro-4-methoxyphenyl)-2-phenylethylidene]hydroxylamine Chemical compound C1=C(F)C(OC)=CC=C1C(=NO)CC1=CC=CC=C1 ULQNIOVTGLPBKJ-UHFFFAOYSA-N 0.000 description 1
- BOLGSPMFWOCQJU-UHFFFAOYSA-N n-[2-(4-methylsulfanylphenyl)-1-phenylethylidene]hydroxylamine Chemical compound C1=CC(SC)=CC=C1CC(=NO)C1=CC=CC=C1 BOLGSPMFWOCQJU-UHFFFAOYSA-N 0.000 description 1
- WJNQCZYLIZZQGJ-UHFFFAOYSA-N n-[2-[4-bromo-n-[(3-methylimidazol-4-yl)methyl]anilino]ethyl]-1-methyl-n-(pyridin-2-ylmethyl)imidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)N(CCN(CC=2N(C=NC=2)C)C=2C=CC(Br)=CC=2)CC=2N=CC=CC=2)=C1 WJNQCZYLIZZQGJ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000013315 neuromuscular junction disease Diseases 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZDRQMXCSSAPUMM-UHFFFAOYSA-N oncrasin-1 Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2C(C=O)=C1 ZDRQMXCSSAPUMM-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- SJGALSBBFTYSBA-UHFFFAOYSA-N oxaziridine Chemical compound C1NO1 SJGALSBBFTYSBA-UHFFFAOYSA-N 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
- 229950009638 tepoxalin Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CMHHITPYCHHOGT-UHFFFAOYSA-N tributylborane Chemical compound CCCCB(CCCC)CCCC CMHHITPYCHHOGT-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式(I): [式中、R1は、アルキル、カルボキシアルキル、アルコキシカルボニル、アミ ノカルボニル、アミノカルボニルアルキル、アルコキシカルボニルアルキル、カ ルボキシル、シアノ、アルコキシ、ハロアルコキシ、アラルコキシ、ヘテロアラ ルコキシ、シクロアルキルアルコキシ、アルキルチオ、アラルキルチオ、ヘテロ アラルキルチオ、シクロアルキルアルキルチオ、アルコキシアルキル、アラルコ キシアルキル、アルキルチオアルキル、アラルキルチオアルキル、アルキルアミ ノアルキル、アリールオキシアルキル、アリールチオアルキル、ヒドロキシル、 アミノ、ヒドロキシアルキル、ハロアルキル、シクロアルキル、シクロアルキル アルキル、ヘテロシクロ、ヘテロシクロアルキル、アラルキル、ハロ、アルキル アミノ、アラルキルアミノ、N−アルキル−N−アラルキルアミノ、ヘテロアラ ルキルアミノ、N−アルキル−N−ヘテロアラルキルアミノ、N−アルキル−N −シクロアルキルアルキルアミノ、アルコキシアルキルオキシアルキル、アリー ル(ヒドロキシアルキル)、ハロアルキルスルホニルオキシ、アリールカルボニ ルオキシアルキル、アリールカルボニルチオアルキル、アルコキシカルボニルオ キシアルキル、カルボキシアルコキシアルキル、カルボキシアリールオキシアル キル、アルコキシカルボニルアリールオキシアルキル、アルキルアミノカルボニ ルオキシアルキル、アルコキシカルボニルチオアルキル、およびアルキルアミノ カルボニルチオアルキルから選択され; R2は、アルキルスルホニル、ヒドロキシスルホニル、およびアミノスルホニ ルから選択され;そして R3は、シクロアルキル、シクロアルケニル、アリールおよびヘテロシクロか ら 選択され、R3は、場合により、置換可能な位置で、アルキル、シアノ、カルボ キシル、アルコキシカルボニル、ハロアルキル、ヒドロキシル、ヒドロキシアル キル、ハロアルコキシ、アミノ、アルキルアミノ、アリールアミノ、アミノアル キル、ニトロ、アルコキシアルキル、アルキルスルフィニル、アルキルスルホニ ル、アミノスルホニル、ハロ、アルコキシおよびアルキルチオから独立に選択さ れる、1つまたはそれ以上の基で置換されていてもよい(但し、R2−置換フェ ニル基がイソオキサゾールの3位にあるとき、R2は、アミノスルホニルである )]の化合物、または薬剤学的に許容しうるその塩。 2.R1が、ヒドロキシル、アミノ、低級アルキル、低級カルボキシアルキル、 低級アルコキシカルボニル、アミノカルボニル、カルボキシル、シアノ、低級ア ミノカルボニルアルキル、低級アルコキシカルボニルアルキル、低級アルコキシ 、低級ハロアルコキシ、低級アラルコキシ、低級ヘテロアラルコキシ、低級シク ロアルキルアルコキシ、低級アルキルチオ、低級アラルキルチオ、低級ヘテロア ラルキルチオ、低級シクロアルキルアルキルチオ、低級アルコキシアルキル、低 級アルコキシアルキルオキシアルキル、低級アラルコキシアルキル、低級アルキ ルチオアルキル、低級アラルキルチオアルキル、低級アルキルアミノアルキル、 低級アリールオキシアルキル、低級アリールチオアルキル、低級ヒドロキシアル キル、低級ハロアルキル、低級シクロアルキル、低級シクロアルキルアルキル、 5員または6員ヘテロシクロ、低級ヘテロシクロアルキル、低級アラルキル、ハ ロ、低級ハロアルキルスルホニルオキシ、低級アリール(ヒドロキシアルキル) 、低級アルキルアミノ、低級アラルキルアミノ、低級N−アルキル−N−アラル キルアミノ、低級ヘテロアラルキルアミノ、低級N−アルキル−N−ヘテロアラ ルキルアミノ、低級N−アルキル−N−シクロアルキルアルキルアミノ、低級ア リールカルボニルオキシアルキル、低級アルコキシカルボニルオキシアルキル、 低級アルキルアミノカルボニルオキシアルキル、低級カルボキシアルコキシアル キル、低級カルボキシアリールオキシアルキル、低級アルコキシカルボニルアリ ールオキシアルキル、低級アルコキシカルボニルチオアルキル、および低級アル キルアミノカルボニルチオアルキルから選択され;R2が、低級アルキルスルホ ニル、ヒドロキシルスルホニル、およびアミノスルホニルから選択され;そして R3が、低 級シクロアルキル、低級シクロアルケニル、アリール、およびヘテロアリールか ら選択され、R3は、場合により、置換可能な位置で、低級アルキルスルフィニ ル、低級アルキル、シアノ、カルボキシル、低級アルコキシカルボニル、低級ハ ロアルキル、ヒドロキシル、低級ヒドロキシアルキル、低級ハロアルコキシ、ア ミノ、低級アルキルアミノ、低級アリールアミノ、低級アミノアルキル、ニトロ 、ハロ、低級アルコキシ、低級アルキルスルホニル、アミノスルホニル、および 低級アルキルチオから独立に選択される、1つまたはそれ以上の基で置換されて いてもよい、請求の範囲第1項記載の化合物;または薬剤学的に許容しうるその 塩。 3.R1が、ヒドロキシル、低級アルキル、カルボキシル、ハロ、低級カルボキ シアルキル、低級アルコキシカルボニルアルキル、低級アラルキル、低級アルコ キシアルキル、低級アルコキシアルキルオキシアルキル、低級アラルコキシアル キル、低級ハロアルキル、低級ハロアルキルスルホニルオキシ、低級ヒドロキシ アルキル、低級アリール(ヒドロキシルアルキル)、低級カルボキシアルコキシ アルキル、低級カルボキシアリールオキシアルキル、低級アルコキシカルボニル アリールオキシアルキル、低級シクロアルキルおよび低級シクロアルキルアルキ ルから選択され;R2が、メチルスルホニル、ヒドロキシスルホニル、およびア ミノスルホニルから選択され;そしてR3が、フェニルおよび5〜6員ヘテロア リールから選択され、R3は、場合により、置換可能な位置で、低級アルキルス ルフィニル、低級アルキル、シアノ、カルボキシル、低級アルコキシカルボニル 、低級ハロアルキル、ヒドロキシル、低級ヒドロキシアルキル、低級ハロアルコ キシ、アミノ、低級アルキルアミノ、低級アリールアミノ、低級アミノアルキル 、ニトロ、ハロ、低級アルコキシ、アミノスルホニル、および低級アルキルチオ から独立に選択される、1つまたはそれ以上の基で置換されていてもよい、請求 の範囲第2項記載の化合物;または薬剤学的に許容しうるその塩。 4.R1が、ヒドロキシル、メチル、エチル、プロピル、イソプロピル、ブチル 、tert−ブチル、イソブチル、ペンチル、イソペンチル、ネオペンチル、ヘ キシル、クロロ、カルボキシル、カルボキシプロピル、カルボキシメチル、カル ボキシエチル、カルボキシブチル、カルボキシペンチル、メトキシカルボニルメ チル、メトキシカルボニルエチル、メトキシメチル、メトキシエチルオキシメチ ル、 ベンジルオキシメチル、フェニルエトキシメチル、フルオロメチル、ジフルオロ メチル、クロロメチル、ジクロロメチル、トリクロロメチル、ペンタフルオロエ チル、ヘプタフルオロプロピル、フルオロメチル、ジフルオロエチル、ジフルオ ロプロピル、ジクロロエチル、ジクロロプロピル、ヒドロキシルメチル、ヒドロ キシルプロピル、ヒドロキシルエチル、トリフルオロメチルスルホニルオキシ、 2−(4−クロロフェニル)−2−ヒドロキシルエチル、カルボキシメトキシメ チル、(4−カルボキシフェニル)オキシメチル、(4−メトキシカルボニルフ ェニル)オキシメチル、シクロヘキシル、シクロブチル、シクロペンチル、シク ロヘプチル、シクロヘキシルメチル、シクロヘキシルエチル、シクロブチルエチ ル、シクロペンチルメチル、シクロヘプチルプロピル、並びにベンジルおよびフ ェニルエチルから選択される低級アラルキル(ここで、フェニル環は、場合によ り、置換可能な位置で、フルオロ、クロロ、ブロモ、ヨード、メチル、およびメ トキシで置換されていてもよい)から選択され;R2が、メチルスルホニル、ヒ ドロキシスルホニル、およびアミノスルホニルから選択され;そしてR3が、フ ェニル、ピリジル、チエニル、チアゾリル、オキサゾリルおよびフリルから選択 され、R3は、場合により、置換可能な位置で、トリフルオロメトキシ、N−メ チルアミノ、N,N−ジメチルアミノ、N−エチルアミノ、N,N−ジプロピル アミノ、N−ブチルアミノ、N−メチル−N−エチルアミノ、フェニルアミノ、 N−メチル−N−フェニルアミノ、メチルスルフィニル、エチルスルフィニル、 メチル、エチル、イソプロピル、ブチル、tert−ブチル、イソブチル、ペン チル、ヘキシル、シアノ、カルボキシル、メトキシカルボニル、フルオロメチル 、ジフルオロメチル、トリフルオロメチル、クロロメチル、ジクロロメチル、ト リクロロメチル、ペンタフルオロエチル、ヘプタフルオロプロピル、フルオロメ チル、ジフルオロエチル、ジフルオロプロピル、ジクロロエチル、ジクロロプロ ピル、ヒドロキシル、ヒドロキシメチル、アミノ、ニトロ、フルオロ、クロロ、 ブロモ、ヨード、メトキシ、エトキシ、プロポキシ、n−ブトキシ、ペントキシ 、ヘキシルオキシ、メチレンジオキシ、アミノスルホニル、メチルチオ、エチル チオ、ブチルチオ、およびヘキシルチオから独立に選択される、1つまたはそれ 以上の基で置換されていてもよい、請求の範囲第3項記載の化合物;または薬剤 学的に許 容しうるその塩。 5.式(II): [式中、R4は、ヒドロキシル、低級アルキル、カルボキシル、ハロ、低級カル ボキシアルキル、低級アルコキシカルボニルアルキル、低級アラルキル、低級ア ルコキシアルキル、低級アルコキシアルキルオキシアルキル、低級アラルコキシ アルキル、低級ハロアルキル、低級ハロアルキルスルホニルオキシ、低級ヒドロ キシルアルキル、低級アリール(ヒドロキシルアルキル)、低級カルボキシアル コキシアルキル、低級カルボキシアリールオキシアルキル、低級アルコキシカル ボニルアリールオキシアルキル、低級シクロアルキルおよび低級シクロアルキル アルキルから選択され;R5は、メチル、ヒドロキシ、およびアミノから選択さ れ;そしてR6は、アリールおよび5〜6員ヘテロアリールから選択され、R6は 、場合により、置換可能な位置で、低級アルキルスルフィニル、低級アルキル、 シアノ、カルボキシル、低級アルコキシカルボニル、低級ハロアルキル、ヒドロ キシル、低級ヒドロキシアルキル、低級ハロアルコキシ、アミノ、低級アルキル アミノ、低級アリールアミノ、低級アミノアルキル、ニトロ、ハロ、低級アルコ キシ、アミノスルホニル、および低級アルキルチオから独立に選択される、1つ またはそれ以上の基で置換されていてもよい]の化合物、または薬剤学的に許容 しうるその塩。 6.R4が、ヒドロキシル、メチル、エチル、プロピル、イソプロピル、ブチル 、tert−ブチル、イソブチル、ペンチル、イソペンチル、ネオペンチル、ヘ キシル、クロロ、カルボキシル、カルボキシプロピル、カルボキシメチル、カル ボキシエチル、カルボキシブチル、カルボキシペンチル、メトキシカルボニルメ チ ル、メトキシカルボニルエチル、メトキシメチル、メトキシエチルオキシメチル 、ベンジルオキシメチル、フェニルエトキシメチル、フルオロメチル、ジフルオ ロメチル、クロロメチル、ジクロロメチル、トリクロロメチル、ペンタフルオロ エチル、ヘプタフルオロプロピル、フルオロメチル、ジフルオロエチル、ジフル オロプロピル、ジクロロエチル、ジクロロプロピル、ヒドロキシルメチル、ヒド ロキシルプロピル、ヒドロキシルエチル、トリフルオロメチルスルホニルオキシ 、2−(4−クロロフェニル)−2−ヒドロキシエチル、(4−カルボキシフェ ニル)オキシメチル、カルボキシメトキシメチル、(4−メトキシカルボニルフ ェニル)オキシメチル、シクロヘキシル、シクロブチル、シクロペンチル、シク ロヘプチル、シクロヘキシルメチル、シクロヘキシルエチル、シクロブチルエチ ル、シクロペンチルメチル、シクロヘプチルプロピル、並びにベンジルおよびフ ェニルエチルから選択される低級アラルキル(ここで、フェニル環は、場合によ り、置換可能な位置で、フルオロ、クロロ、ブロモ、ヨード、メチル、およびメ トキシで置換されていてもよい)から選択され;R6が、フェニルおよび3−ピ リジルから選択され、R6は、場合により、置換可能な位置で、トリフルオロメ トキシ、N−メチルアミノ、N,N−ジメチルアミノ、N−エチルアミノ、N, N−ジプロピルアミノ、N−ブチルアミノ、N−メチル−N−エチルアミノ、フ ェニルアミノ、N−メチル−N−フェニルアミノ、メチルスルフィニル、エチル スルフィニル、メチル、エチル、イソプロピル、ブチル、tert−ブチル、イ ソブチル、ペンチル、ヘキシル、シアノ、カルボキシル、メトキシカルボニル、 フルオロメチル、ジフルオロメチル、トリフルオロメチル、クロロメチル、ジク ロロメチル、トリクロロメチル、ペンタフルオロエチル、ヘプタフルオロプロピ ル、フルオロメチル、ジフルオロエチル、ジフルオロプロピル、ジクロロエチル 、ジクロロプロピル、ヒドロキシル、ヒドロキシメチル、アミノ、アミノメチル 、ニトロ、フルオロ、クロロ、ブロモ、ヨード、メトキシ、エトキシ、プロポキ シ、n−ブトキシ、ペントキシ、ヘキシルオキシ、メチレンジオキシ、メチルチ オ、エチルチオ、ブチルチオ、およびヘキシルチオから独立に選択される、1つ またはそれ以上の基で置換されていてもよい、請求の範囲第5項記載の化合物; または薬剤学的に許容しうるその塩。 7.以下の群よりなる化合物および薬剤学的に許容しうるその塩から選択される 請求の範囲第6項記載の化合物: [4−[4−(アミノスルホニル)フェニル]−3−フェニルイソオキサゾー ル−5−イル]−3−メチルブタン−1−酸; [[4−[4−(アミノスルホニル)フェニル]−3−フェニルイソオキサゾ ール−5−イル]メトキシ]酢酸; 4−[4−[4−(アミノスルホニル)フェニル]]−3−フェニルイソオキ サゾール−5−イル]ブタン酸; 4−[5−シアノ−3−フェニルイソオキサゾール−4−イル]ベンゼンスル ホンアミド; 4−[5−クロロ−3−フェニルイソオキサゾール−4−イル]ベンゼンスル ホンアミド; 4−[3−フェニル−5−(トリフルオロメタンスルホンオキシ)イソオキサ ゾール−4−イル]ベンゼンスルホンアミド; 4−[3−(3,5−ジフルオロフェニル)−5−メチルイソオキサゾール− 4−イル]ベンゼンスルホンアミド; 4−[3−(4−ブロモフェニル)−5−メチルイソオキサゾール−4−イル ]ベンゼンスルホンアミド; 4−[5−ジフルオロメチル−3−(3−フルオロ−4−メトキシフェニル) イソオキサゾール−4−イル]ベンゼンスルホンアミド; 4−[5−ジフルオロメチル−3−(4−メチルシフェニル)イソオキサゾー ル−4−イル]ベンゼンスルホンアミド; 4−[5−ジフルオロメチル−3−(4−メトキシフェニル)イソオキサゾー ル−4−イル]ベンゼンスルホンアミド; 5−ジフルオロメチル−4−(4−メチルスルホニルフェニル)−3−フェニ ルイソオキサゾール; 4−[3−(3−クロロフェニル)−5−メチルイソオキサゾール−4−イル ]ベンゼンスルホンアミド; 4−[3−(3,4−ジフルオロフェニル)−5−メチルイソオキサゾール− 4−イル]ベンゼンスルホンアミド; 4−[[4−[4−(アミノスルホニル)フェニル]−3−フェニルイソオキ サゾール−5−イル]メトキシ]安息香酸メチル; 4−[[4−[4−(アミノスルホニル)フェニル]−3−フェニルイソオキ サゾール−5−イル]メトキシ]安息香酸; 4−[5−エチル−3−フェニルイソオキサゾール−4−イル]ベンゼンスル ホンアミド; 4−[3−フェニル−5−プロピルイソオキサゾール−4−イル]ベンゼンス ルホンアミド; 4−[5−イソプロピル−3−フェニルイソオキサゾール−4−イル]ベンゼ ンスルホンアミド; 4−[5−ブチル−3−フェニルイソオキサゾール−4−イル]ベンゼンスル ホンアミド; 4−[5−イソブチル−3−フェニルイソオキサゾール−4−イル]ベンゼン スルホンアミド; 4−[5−シクロヘキシル−3−フェニルイソオキサゾール−4−イル]ベン ゼンスルホンアミド; 4−[5−ネオペンチル−3−フェニルイソオキサゾール−4−イル]ベンゼ ンスルホンアミド; 4−[5−シクロヘキシルメチル−3−フェニルイソオキサゾール−4−イル ]ベンゼンスルホンアミド; 4−[5−(4−クロロフェニル)メチル−3−フェニルイソオキサゾール− 4−イル]ベンゼンスルホンアミド; 4−[5−ジフルオロメチル−3−フェニルイソオキサゾール−4−イル]ベ ンゼンスルホンアミド; 4−[5−クロロメチル−3−フェニルイソオキサゾール−4−イル]ベンゼ ンスルホンアミド; 4−[5−メチル−3−フェニルイソオキサゾール−4−イル]ベンゼンスル ホン酸; 4−[3−フェニル−5−プロピルイソオキサゾール−4−イル]ベンゼンス ルホン酸; 4−[5−メトキシメチル−3−フェニルイソオキサゾール−4−イル]ベン ゼンスルホンアミド; 4−[5−(3−ヒドロキシプロピル)−3−フェニルイソオキサゾール−4 −イル]ベンゼンスルホンアミド; 4−[3−(4−クロロフェニル)−5−メチル−イソオキサゾール−4−イ ル]ベンゼンスルホンアミド; 4−[3−(4−フルオロフェニル)−5−メチル−イソオキサゾール−4− イル]ベンゼンスルホンアミド; 4−[3−(3−フルオロ−4−メチルフェニル)−5−メチル−イソオキサ ゾール−4−イル]ベンゼンスルホンアミド; 4−[3−(3−クロロ−4−メチルフェニル)−5−メチル−イソオキサゾ ール−4−イル]ベンゼンスルホンアミド; 4−[5−メチル−3−(3−ピリジル)イソオキサゾール−4−イル]ベン ゼンスルホンアミド; 4−[3−(3−フルオロフェニル)−5−メチル−イソオキサゾール−4− イル]ベンゼンスルホンアミド; 4−[5−ヒドロキシメチル−3−フェニルイソオキサゾール−4−イル]ベ ンゼンスルホンアミド; 4−[4−(アミノスルホニル)フェニル]−3−フェニルイソオキサゾール −5−イル]カルボン酸; 4−[5−ヒドロキシ−3−フェニル−4−イソオキサゾリル]ベンゼンスル ホンアミド; 4−[5−メチル−3−フェニル−イソオキサゾール−4−イル]ベンゼンス ルホンアミド; 4−[3−(3−フルオロ−4−メトキシフェニル)−5−メチル−イソオキ サゾール−4−イル]ベンゼンスルホンアミド; 5−メチル−4−[4−(メチルスルホニル)フェニル]−3−イソオキサゾ ール; 4−[3−フェニル−5−(3,3,3−トリフルオロ−2−オキソプロピル )イソオキサゾール−4−イル]ベンゼンスルホンアミド; [3−(3−クロロ−4−メトキシフェニル)−5−メチル−4−[4−(メ チルスルホニル)フェニル]イソオキサゾール; [4−[4−アミノスルホニル)フェニル]−3−フェニル−イソオキサゾー ル−5−イル]酢酸; [4−[4−アミノスルホニル)フェニル]−3−フェニル−イソオキサゾー ル−5−イル]プロパン酸; [4−[4−アミノスルホニル)フェニル]−3−フェニル−イソオキサゾー ル−5−イル]プロパン酸エチル; [3−(3−フルオロ−4−メトキシフェニル)−4−[4−(メチルスルホ ニル)フェニル]イソオキサゾール−5−イル]酢酸;および [4−[4−(アミノスルホニル)フェニル]−3−(3−フルオロ−4−メ トキシフェニル)イソオキサゾール−5−イル]プロパン酸。 8.4−[5−メチル−3−フェニル−イソオキサゾール−4−イル]ベンゼン スルホンアミドである、請求の範囲第6項記載の化合物;または薬剤学的に許容 しうるその塩。 9.4−[5−ヒドロキシメチル−3−フェニルイソオキサゾール−4−イル] ベンゼンスルホンアミドである、請求の範囲第6項記載の化合物;または薬剤学 的に許容しうるその塩。 10.式(III): [式中、R7は、ヒドロキシル、低級アルキル、カルボキシル、ハロ、低級カル ボキシアルキル、低級アルコキシカルボニルアルキル、低級アルコキシアルキル 、低級カルボキシアルコキシアルキル、低級ハロアルキル、低級ハロアルキルス ルホニルオキシ、低級ヒドロキシアルキル、低級アリール(ヒドロキシルアルキ ル)、低級カルボキシアリールオキシアルキル、低級アルコキシカルボニルアリ ールオキシアルキル、低級シクロアルキル、低級シクロアルキルアルキル、およ び低級アラルキルから選択され;そしてR8は、ヒドリド、低級アルキルスルフ ィニル、低級アルキル、シアノ、カルボキシル、低級アルコキシカルボニル、低 級ハロアルキル、ヒドロキシル、低級ヒドロキシアルキル、低級ハロアルコキシ 、アミノ、低級アルキルアミノ、低級アリールアミノ、低級アミノアルキル、ニ トロ、ハロ、低級アルコキシ、アミノスルホニル、および低級アルキルチオから 独立に選択される、1つまたはそれ以上の基である]の化合物、または薬剤学的 に許容しうるその塩。 11.式(IV): [式中、R9は、低級アルキル、低級カルボキシアルキル、低級アルコキシカル ボニルアルキル、低級アルコキシアルキルオキシアルキル、低級ヒドロキシルア ルキル、および低級アラルキルから選択され;R10は、ヒドリド、低級アルキル 、低級ハロアルキル、ハロ、および低級アルコキシから独立に選択される、1つ またはそれ以上の基であり、そしてR11は、メチルおよびアミノから選択される ]の化合物、または薬剤学的に許容しうるその塩。 12.R9が、メチル、エチル、プロピル、イソプロピル、ブチル、tert− ブチル、イソブチル、ペンチル、イソペンチル、ネオペンチル、ヘキシル、カル ボ キシプロピル、カルボキシメチル、カルボキシエチル、カルボキシブチル、カル ボキシペンチル、メトキシカルボニルメチル、メトキシカルボニルエチル、メト キシエチルオキシメチル、ヒドロキシメチル、ヒドロキシプロピル、ヒドロキシ エチル、並びにベンジルおよびフェニルエチルから選択される低級アラルキル( ここで、フェニル環は、場合により、置換可能な位置で、フルオロ、クロロ、ブ ロモ、ヨード、メチル、およびメトキシで置換されていてもよい)から選択され ;R10が、ヒドリド、メチル、エチル、イソプロピル、ブチル、tert−ブチ ル、イソブチル、ペンチル、ヘキシル、フルオロメチル、ジフルオロメチル、ト リフルオロメチル、クロロメチル、ジクロロメチル、トリクロロメチル、ペンタ フルオロエチル、ヘプタフルオロプロピル、フルオロメチル、ジフルオロエチル 、ジフルオロプロピル、ジクロロエチル、ジクロロプロピル、フルオロ、クロロ 、ブロモ、ヨード、メトキシ、エトキシ、プロポキシ、n−ブトキシ、ペントキ シ、およびメチレンジオキシから独立に選択される、1つまたはそれ以上の基で ある、請求の範囲第11項記載の化合物;または薬剤学的に許容しうるその塩。 13.以下の群よりなる化合物および薬剤学的に許容しうるその塩から選択され る請求の範囲第12項記載の化合物: 4−[3−エチル−5−フェニルイソオキサゾール−4−イル]ベンゼンスル ホンアミド; 4−[3−イソプロピル−5−フェニルイソオキサゾール−4−イル]ベンゼ ンスルホンアミド; 4−[5−フェニル−3−プロピルイソオキサゾール−4−イル]ベンゼンス ルホンアミド; 4−[3−エチル−5−(4−メチルフェニル)イソオキサゾール−4−イル ]ベンゼンスルホンアミド; 4−[3−ブチル−5−フェニルイソオキサゾール−4−イル]ベンゼンスル ホンアミド; 4−[3−メチル−5−フェニルイソオキサゾール−4−イル]ベンゼンスル ホンアミド; 4−[3−メチル−5−(4−メチルフェニル)イソオキサゾール−4−イル ] ベンゼンスルホンアミド; 4−[5−(4−クロロフェニル)−3−メチルイソオキサゾール−4−イル ]ベンゼンスルホンアミド; 4−[5−(4−フルオロフェニル)−3−メチルイソオキサゾール−4−イ ル]ベンゼンスルホンアミド; 4−[3−メチル−5−(3−クロロフェニル)イソオキサゾール−4−イル ]ベンゼンスルホンアミド; 4−[3−ヒドロキシメチル−5−フェニルイソオキサゾール−4−イル]ベ ンゼンスルホンアミド; 4−(4−アミノスルホニルフェニル)−5−フェニル−イソオキサゾール− 3−酢酸; 3−メチル−4−(4−メチルスルホニルフェニル)−5−フェニルイソオキ サゾール; 4−[3−[2−(4−クロロフェニル)−2−ヒドロキシエチル]−5−フ ェニルイソオキサゾール−4−イル]ベンゼンスルホンアミド; 3−エチル−4−(4−メチルスルホニルフェニル)−5−フェニルイソオキ サゾール; 4−[3−エチル−5−(4−フルオロフェニル)イソオキサゾール−4−イ ル]ベンゼンスルホンアミド; 4−[3−エチル−5−(3−フルオロフェニル)イソオキサゾール−4−イ ル]ベンゼンスルホンアミド; 4−[3−エチル−5−(3−メチルフェニル)イソオキサゾール−4−イル ]ベンゼンスルホンアミド; 4−[3−エチル−5−(2−フルオロフェニル)イソオキサゾール−4−イ ル]ベンゼンスルホンアミド; 4−[3−エチル−5−(2−メチルフェニル)イソオキサゾール−4−イル ]ベンゼンスルホンアミド; 4−[5−(3−クロロ−4−メトキシフェニル)−3−エチルイソオキサゾ ール−4−イル]ベンゼンスルホンアミド; 4−[3−エチル−5−(3−フルオロ−4−メトキシフェニル)イソオキサ ゾール−4−イル]ベンゼンスルホンアミド; 4−[3−エトキシエチルオキシメチル−5−フェニルイソオキサゾール−4 −イル]ベンゼンスルホンアミド; 4−[3−エチル−5−(3−フルオロ−4−メチルフェニル)イソオキサゾ ール−4−イル]ベンゼンスルホンアミド; 4−[3−イソブチル−5−フェニルイソオキサゾール−4−イル]ベンゼン スルホンアミド; 4−[3−ベンジル−5−フェニルイソオキサゾール−4−イル]ベンゼンス ルホンアミド; 4−(4−アミノスルホニルフェニル)−5−フェニル−イソオキサゾール− 3−プロパン酸; 4−(4−アミノスルホニルフェニル)−5−フェニル−イソオキサゾール− 3−ブタン酸; 4−(4−アミノスルホニルフェニル)−5−フェニル−イソオキサゾール− 3−ペンタン酸;および 4−(4−アミノスルホニルフェニル)−5−フェニル−イソオキサゾール− 3−ヘキサン酸。 14.式(V): [式中、R12は、ヒドリド、ハロ、低級ハロアルキル、低級アルコキシおよび低 級アルキルから独立に選択される、1つまたはそれ以上の基であり;R13は、低 級アルキル、低級カルボキシアルキル、低級アルコキシカルボニルアルキルおよ び低級アラルキルから選択され;そしてR14は、メチルおよびアミノから選択さ れる]の化合物、または薬剤学的に許容しうるその塩 15.R12が、ヒドリド、メチル、エチル、イソプロピル、ブチル、tert− ブチル、イソブチル、ペンチル、フルオロメチル、ジフルオロメチル、トリフル オロメチル、クロロメチル、ジクロロメチル、トリクロロメチル、ペンタフルオ ロエチル、ヘプタフルオロプロピル、フルオロメチル、ジフルオロエチル、ジフ ルオロプロピル、ジクロロエチル、ジクロロプロピル、フルオロ、クロロ、ブロ モ、ヨード、メトキシ、エトキシ、プロポキシ、n−ブトキシ、ペントキシ、お よびメチレンジオキシから独立に選択される、1つまたはそれ以上の基であり; R13が、メチル、エチル、プロピル、イソプロピル、ブチル、tert−ブチル 、イソブチル、ペンチル、イソペンチル、ネオペンチル、ヘキシル、カルボキシ プロピル、カルボキシメチル、カルボキシエチル、カルボキシブチル、カルボキ シペンチル、メトキシカルボニルメチル、メトキシカルボニルエチル、並びにベ ンジルおよびフェニルエチルから選択される低級アラルキル(ここで、フェニル 環は、場合により、置換可能な位置で、フルオロ、クロロ、ブロモ、ヨード、メ チル、およびメトキシで置換されていてもよい)から選択される、請求の範囲第 14項記載の化合物;または薬剤学的に許容しうるその塩。 16.以下の群よりなる化合物および薬剤学的に許容しうるその塩から選択され る請求の範囲第15項記載の化合物: 4−[4−(4−クロロフェニル)−3−メチルイソオキサゾール−5−イル ]ベンゼンスルホンアミド; 4−[4−(4−フルオロフェニル)−3−メチルイソオキサゾール−5−イ ル]ベンゼンスルホンアミド; 3−メチル−5−(4−メチルスルホニルフェニル)−4−フェニルイソオキ サゾール; 4−[3−メチル−4−フェニルイソオキサゾール−5−イル]ベンゼンスル ホンアミド; 5−(4−アミノスルホニルフェニル)−4−フェニル−イソオキサゾール− 3−プロパン酸; 5−(4−アミノスルホニルフェニル)−4−フェニル−イソオキサゾール− 3−ブタン酸; 5−(4−アミノスルホニルフェニル)−4−フェニル−イソオキサゾール− 3−ペンタン酸; 5−(4−アミノスルホニルフェニル)−4−フェニル−イソオキサゾール− 3−ヘキサン酸; 4−[3−エチル−4−フェニルイソオキサゾール−5−イル]ベンゼンスル ホンアミド; 4−[3−イソプロピル−4−フェニルイソオキサゾール−5−イル]ベンゼ ンスルホンアミド; 4−[3−イソブチル−4−フェニルイソオキサゾール−5−イル]ベンゼン スルホンアミド; 4−[3−ベンジル−4−フェニルイソオキサゾール−5−イル]ベンゼンス ルホンアミド; 4−[3−プロピル−4−フェニルイソオキサゾール−5−イル]ベンゼンス ルホンアミド; 4−[3−メチル−4−(4−メチルフェニル)イソオキサゾール−5−イル ]ベンゼンスルホンアミド; 4−[3−メチル−4−(4−トリフルオロメチルフェニル)イソオキサゾー ル−5−イル]ベンゼンスルホンアミド; 4−[3−エチル−4−(4−メチルフェニル)イソオキサゾール−5−イル ]ベンゼンスルホンアミド; 4−[3−エチル−4−(4−トリフルオロメチルフェニル)イソオキサゾー ル−5−イル]ベンゼンスルホンアミド;および 4−[3−エチル−4−(4−フルオロフェニル)イソオキサゾール−5−イ ル]ベンゼンスルホンアミド。 17.請求の範囲第1、2、3、4、5、6、7、8、9、10、11、12、 13、14、15、または16項記載の化合物のファミリーから選択される化合 物、あるいは薬剤学的に許容しうるその塩の治療的に有効量からなる薬剤組成物 。 18.被検体の炎症または炎症関連疾患の治療方法であって、請求の範囲第1、 2、3、4、5、6、7、8、9、10、11、12、13、14、15、また は16項記載の化合物あるいは薬剤学的に許容しうるその塩を用いて、そのよう な疾患を有するかまたは罹りやすい被検体を治療する上記方法。 19.炎症の治療に使用するための、請求の範囲第18項記載の方法。 20.炎症関連疾患の治療に使用するための、請求の範囲第18項記載の方法。 21.炎症関連疾患は関節炎である、請求の範囲第20項記載の方法。 22.炎症関連疾患は疼痛である、請求の範囲第20項記載の方法。 23.炎症関連疾患は発熱である、請求の範囲第20項記載の方法。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US387,680 | 1989-07-31 | ||
| US38768095A | 1995-02-13 | 1995-02-13 | |
| US08/387,680 | 1995-02-13 | ||
| US08/473,884 | 1995-06-07 | ||
| US08/473,884 US5633272A (en) | 1995-02-13 | 1995-06-07 | Substituted isoxazoles for the treatment of inflammation |
| US473,884 | 1995-06-07 | ||
| PCT/US1996/001869 WO1996025405A1 (en) | 1995-02-13 | 1996-02-12 | Substituted isoxazoles for the treatment of inflammation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001326343A Division JP2002179656A (ja) | 1995-02-13 | 2001-10-24 | 炎症の治療のための置換イソオキサゾール |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11503722A true JPH11503722A (ja) | 1999-03-30 |
| JP3267300B2 JP3267300B2 (ja) | 2002-03-18 |
Family
ID=27011981
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52505796A Expired - Fee Related JP3267300B2 (ja) | 1995-02-13 | 1996-02-12 | 炎症の治療のための置換イソオキサゾール |
| JP2001326343A Pending JP2002179656A (ja) | 1995-02-13 | 2001-10-24 | 炎症の治療のための置換イソオキサゾール |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001326343A Pending JP2002179656A (ja) | 1995-02-13 | 2001-10-24 | 炎症の治療のための置換イソオキサゾール |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US5859257A (ja) |
| EP (1) | EP0809636B1 (ja) |
| JP (2) | JP3267300B2 (ja) |
| CN (2) | CN1107058C (ja) |
| AT (1) | ATE223390T1 (ja) |
| AU (1) | AU699593B2 (ja) |
| BR (1) | BR9607035A (ja) |
| CA (1) | CA2212836C (ja) |
| CZ (1) | CZ293211B6 (ja) |
| DE (3) | DE69623444T2 (ja) |
| DK (1) | DK0809636T3 (ja) |
| ES (1) | ES2183935T3 (ja) |
| FI (1) | FI120736B (ja) |
| LU (1) | LU91024I2 (ja) |
| NL (1) | NL300128I2 (ja) |
| NO (2) | NO312066B1 (ja) |
| NZ (2) | NZ302586A (ja) |
| PL (2) | PL185544B1 (ja) |
| PT (1) | PT809636E (ja) |
| RO (1) | RO119946B1 (ja) |
| RU (1) | RU2200158C2 (ja) |
| WO (1) | WO1996025405A1 (ja) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008001930A1 (en) | 2006-06-28 | 2008-01-03 | Aska Pharmaceutical Co., Ltd. | Pyridylisoxazole derivative |
| JP2010538001A (ja) * | 2007-08-27 | 2010-12-09 | ヘリコン・セラピューティクス・インコーポレーテッド | 治療用イソオキサゾール化合物 |
| JP2012506386A (ja) * | 2008-10-21 | 2012-03-15 | メタボレックス, インコーポレイテッド | アリールgpr120受容体アゴニストおよびその使用 |
Families Citing this family (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6512121B2 (en) | 1998-09-14 | 2003-01-28 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| ZA9756B (en) * | 1996-01-16 | 1997-07-17 | Warner Lambert Co | Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines |
| JP2000504723A (ja) * | 1996-02-13 | 2000-04-18 | ジー.ディー.サール アンド カンパニー | シクロオキシゲナーゼ―2阻害剤および5―リポキシゲナーゼ阻害剤投与の免疫抑制効果 |
| US5908858A (en) * | 1996-04-05 | 1999-06-01 | Sankyo Company, Limited | 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses |
| US5677318A (en) * | 1996-07-11 | 1997-10-14 | Merck Frosst Canada, Inc. | Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents |
| CZ297679B6 (cs) * | 1996-08-14 | 2007-03-07 | G. D. Searle & Co. | Krystalická forma B 4-[5-methyl-3-fenylizoxazol-4-yl]benzensulfonamidu |
| DE69729946T2 (de) | 1996-10-15 | 2005-01-20 | G.D. Searle Llc | Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia |
| US5985930A (en) | 1996-11-21 | 1999-11-16 | Pasinetti; Giulio M. | Treatment of neurodegenerative conditions with nimesulide |
| US6130334A (en) * | 1998-04-15 | 2000-10-10 | Merck & Co., Inc. | Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors |
| US6127545A (en) * | 1997-04-18 | 2000-10-03 | Merck & Co., Inc. | Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors |
| TW492959B (en) * | 1997-04-18 | 2002-07-01 | Merck & Co Inc | Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors |
| EE200300169A (et) * | 1997-04-18 | 2003-06-16 | G.D. Searle & Co. | Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südame-veresoonkonna haiguste ärahoidmiseks |
| US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
| AU8127298A (en) * | 1997-07-09 | 1999-02-08 | Nippon Soda Co., Ltd. | Isoxazole compounds, process for the preparation thereof, and insecticides and acaricides |
| US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| US6525053B1 (en) | 1997-08-22 | 2003-02-25 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
| AR015938A1 (es) | 1997-09-25 | 2001-05-30 | Merck Sharp & Dohme | Procedimiento para preparar diaril piridinas utiles como inhibidores cox-2 y compuesto intermediario |
| US6025353A (en) * | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
| NZ333399A (en) | 1997-12-24 | 2000-05-26 | Sankyo Co | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis |
| USRE39708E1 (en) | 1998-08-07 | 2007-06-26 | Chiron Corporation | Estrogen receptor modulators |
| EP1102755B1 (en) | 1998-08-07 | 2006-01-04 | Chiron Corporation | Substituted isoxazole derivatives as estrogen receptor modulators |
| WO2000007996A2 (en) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| US6649645B1 (en) | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
| ES2236011T3 (es) * | 1999-12-08 | 2005-07-16 | Pharmacia Corporation | Formas cristalinas polimorficas de celecoxib. |
| PL351069A1 (en) * | 1999-12-08 | 2003-03-10 | Pharmacia Corp | Valdecoxib compositions |
| KR100793668B1 (ko) * | 1999-12-08 | 2008-01-10 | 파마시아 코포레이션 | 강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브 |
| ES2258988T3 (es) * | 1999-12-22 | 2006-09-16 | Pharmacia Corporation | Composiciones de liberacion dual de un inhibidor de la ciclooxigenasa-2. |
| AP2002002582A0 (en) | 1999-12-23 | 2002-09-30 | Nitromed Inc | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| AU2001255600A1 (en) * | 2000-04-25 | 2001-11-07 | Pharmacia Corporation | Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes |
| US20020009421A1 (en) * | 2000-06-01 | 2002-01-24 | Wilder Karol J. | Therapy following skin injury from exposure to ultraviolet radiation |
| JP2004503601A (ja) * | 2000-07-13 | 2004-02-05 | ファルマシア・コーポレーション | 眼のcox−2媒介疾患の処置及び予防におけるcox−2阻害剤の使用法 |
| EP1303265B1 (en) | 2000-07-20 | 2007-07-11 | Lauras AS | Use of cox-2 inhibitors as immunostimulants in the treatment of hiv or aids |
| US6716829B2 (en) | 2000-07-27 | 2004-04-06 | Pharmacia Corporation | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |
| IN191090B (ja) * | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
| CN1263748C (zh) * | 2000-10-18 | 2006-07-12 | 西巴特殊化学品控股有限公司 | 双吲哚化合物的制备方法 |
| WO2002062391A2 (en) * | 2001-02-02 | 2002-08-15 | Pharmacia Corporation | Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea |
| US6673818B2 (en) | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
| US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
| ATE381542T1 (de) * | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| US20030114416A1 (en) * | 2001-08-14 | 2003-06-19 | Pharmacia Corporation | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| US20050101563A1 (en) * | 2001-08-14 | 2005-05-12 | Pharmacia Corporation | Method and compositions for the treatment and prevention of pain and inflammation |
| AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| IL161086A0 (en) * | 2001-10-02 | 2004-08-31 | Pharmacia Corp | Method for preparing benzenesulfonyl compounds |
| US20030212138A1 (en) * | 2002-01-14 | 2003-11-13 | Pharmacia Corporation | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
| WO2003068239A1 (en) * | 2002-02-12 | 2003-08-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel drugs for external use |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| AU2003213719A1 (en) | 2002-03-01 | 2003-09-16 | Regents Of The University Of Michigan | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| JP4471262B2 (ja) * | 2002-03-07 | 2010-06-02 | 株式会社エス・ディー・エス バイオテック | 置換イソキサゾールアルキルアミン誘導体及び農園芸用殺菌剤 |
| PT1492773E (pt) * | 2002-04-05 | 2009-05-07 | Cadila Healthcare Ltd | Compostos de 4-(heterociclilo)-benzenossulfoximinapara o tratamento da inflamação |
| US7329401B2 (en) | 2002-04-15 | 2008-02-12 | The Regents Of The University Of California | Cyclooxygenase-2 selective agents useful as imaging probes and related methods |
| IL165383A0 (en) | 2002-06-21 | 2006-01-15 | Transform Pharmaceuticals Inc | Pharmaceutical compositions with improved dissolution |
| ITMI20021391A1 (it) | 2002-06-25 | 2003-12-29 | Nicox Sa | Nitroderivati di inibitori della cicloossigenasi-2 |
| US7087630B2 (en) | 2002-06-27 | 2006-08-08 | Nitromed, Inc. | Cyclooxygenase 2 selective inhibitors, compositions and methods of use |
| JP2005535642A (ja) | 2002-06-28 | 2005-11-24 | ニトロメッド インコーポレーティッド | オキシムおよび/またはヒドラゾンを含有するニトロソ化および/またはニトロシル化シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法 |
| BR0312708A (pt) * | 2002-07-17 | 2005-04-26 | Warner Lambert Co | Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com celecoxib ou valdecoxib |
| AU2003281169A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| BR0312943A (pt) * | 2002-07-17 | 2005-07-12 | Warner Lambert Co | Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| AU2003267231A1 (en) * | 2002-09-20 | 2004-04-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| KR100484525B1 (ko) * | 2002-10-15 | 2005-04-20 | 씨제이 주식회사 | 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물 |
| US20040147581A1 (en) * | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
| AU2003303041B2 (en) | 2002-12-13 | 2008-07-24 | Warner-Lambert Company Llc | Alpha-2-delta ligand to treat lower urinary tract symptoms |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| US20040235925A1 (en) * | 2002-12-17 | 2004-11-25 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| ES2215474B1 (es) | 2002-12-24 | 2005-12-16 | J. URIACH & CIA S.A. | Nuevos derivados de fosforamida. |
| US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| AU2003238668A1 (en) | 2003-04-04 | 2004-10-25 | Hetero Drugs Limited | Novel crystalline forms of valdecoxib |
| EP1622630B1 (en) * | 2003-05-07 | 2012-08-29 | Osteologix A/S | Strontium combinations for the prophylaxis/treatment of cartilage and/or bone conditions |
| ES2275218T3 (es) | 2003-05-07 | 2007-06-01 | Osteologix A/S | Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos. |
| HUP0302219A2 (hu) * | 2003-07-16 | 2005-03-29 | Richter Gedeon Vegyészeti Gyár Rt. | N-hidroxi-4-(3-fenil-5-metil-izoxazol-4-il)-benzolszulfonamid-szolvátok, eljárás előállításukra és alkalmazásuk |
| US20050131028A1 (en) * | 2003-09-11 | 2005-06-16 | Pharmacia Corporation | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders |
| US7067159B2 (en) | 2003-12-05 | 2006-06-27 | New Chapter, Inc. | Methods for treating prostate cancer with herbal compositions |
| US7070816B2 (en) | 2003-12-05 | 2006-07-04 | New Chapter, Inc. | Methods for treating prostatic intraepithelial neoplasia with herbal compositions |
| KR100544347B1 (ko) * | 2003-12-11 | 2006-01-23 | 한국생명공학연구원 | 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물 |
| ITMI20040019A1 (it) * | 2004-01-12 | 2004-04-12 | Univ Bari | Derivati isossazolici e loro impiego come inibitori della ciclossigenasi |
| WO2005123701A1 (en) * | 2004-06-14 | 2005-12-29 | Pharmacia Corporation | Method for the preparation of diarylisoxazole sulfonamide compounds and intermediates |
| US7622142B2 (en) | 2004-09-14 | 2009-11-24 | New Chapter Inc. | Methods for treating glioblastoma with herbal compositions |
| EP1833795B1 (en) | 2004-12-23 | 2009-03-04 | Glaxo Group Limited | Pyridine compounds for the treatment of prostaglandin mediated diseases |
| US7939536B2 (en) | 2004-12-28 | 2011-05-10 | Aska Pharmaceutical Co., Ltd. | Pyrimidinylisoxazole derivatives |
| US7521435B2 (en) | 2005-02-18 | 2009-04-21 | Pharma Diagnostics, N.V. | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same |
| GB0504828D0 (en) * | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| NL2000351C2 (nl) * | 2005-12-22 | 2007-09-11 | Pfizer Prod Inc | Estrogeen-modulatoren. |
| WO2008001929A1 (en) | 2006-06-28 | 2008-01-03 | Aska Pharmaceutical Co., Ltd. | Treatment agent for inflammatory bowel disease |
| WO2008033466A2 (en) * | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
| CA2673545A1 (en) | 2006-12-22 | 2008-07-03 | Recordati Ireland Limited | Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids |
| EP2114461A2 (en) * | 2007-01-19 | 2009-11-11 | Mallinckrodt Inc. | Diagnostic and therapeutic cyclooxygenase-2 binding ligands |
| AU2008215659B2 (en) | 2007-02-16 | 2012-11-01 | Aska Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising microparticle oily suspension |
| GB0704407D0 (en) | 2007-03-07 | 2007-04-18 | Glaxo Group Ltd | Compounds |
| US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
| US7989450B2 (en) | 2008-01-11 | 2011-08-02 | Universita' Degli Studi Di Bari | Functionalized diarylisoxazoles inhibitors of ciclooxygenase |
| TWI365071B (en) * | 2008-02-26 | 2012-06-01 | Univ Kaohsiung Medical | Isoxazole derivatives and pharmaceutical compositions comprising the same |
| WO2009132172A1 (en) * | 2008-04-23 | 2009-10-29 | Vgx Pharmaceuticals, Inc. | Isoxazoline compounds and their use to suppress inflammation or treat inflammatory disease |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| RU2412174C1 (ru) * | 2009-06-19 | 2011-02-20 | Государственное образовательное учреждение высшего профессионального образования "Астраханский государственный университет" (АГУ) | 3-замещенные 4,4(5н)-дикарбонитрил-5-фенилизоксазолины, обладающие противогрибковой активностью |
| WO2011012622A1 (en) | 2009-07-30 | 2011-02-03 | Glaxo Group Limited | Benzoxazinone derivatives for the treatment of glytl mediated disorders |
| WO2011023753A1 (en) | 2009-08-27 | 2011-03-03 | Glaxo Group Limited | Benzoxazine derivatives as glycine transport inhibitors |
| GB201000685D0 (en) | 2010-01-15 | 2010-03-03 | Glaxo Group Ltd | Novel compounds |
| GB201007789D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel Compound |
| GB201007791D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel compounds |
| ES2529233T3 (es) | 2010-07-09 | 2015-02-18 | Convergence Pharmaceuticals Limited | Compuestos tetrazol como bloqueadores de canales de calcio |
| EP2665729B1 (en) | 2011-01-19 | 2015-04-01 | Convergence Pharmaceuticals Limited | Piperazine derivatives as cav2.2 calcium channel blockers |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| CN103172583A (zh) * | 2013-03-07 | 2013-06-26 | 深圳市资福药业有限公司 | 一种制备帕瑞昔布的方法 |
| CN104193694B (zh) * | 2014-09-19 | 2016-08-24 | 成都欣捷高新技术开发有限公司 | 一种制备帕瑞昔布钠中间体的方法 |
| GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| US11583516B2 (en) | 2016-09-07 | 2023-02-21 | Trustees Of Tufts College | Dash inhibitors, and uses related thereto |
| CA3050255A1 (en) * | 2017-01-20 | 2018-07-26 | The Regents Of The University Of California | Inhibitors of the n-terminal domain of the androgen receptor |
| CN109970673B (zh) * | 2017-12-28 | 2021-02-19 | 北京康派森医药科技有限公司 | 帕瑞昔布钠杂质的制备方法 |
| CN108129411A (zh) * | 2017-12-28 | 2018-06-08 | 北京沃邦医药科技有限公司 | 帕瑞昔布钠中间体5-甲基-3,4-二苯基异噁唑的制备方法 |
| RU2684322C1 (ru) * | 2017-12-29 | 2019-04-08 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | 3-арил-5-фторизоксазолы и способ их получения |
| CN108164521B (zh) * | 2018-03-02 | 2020-11-13 | 成都新恒创药业有限公司 | 一种帕瑞昔布钠降解杂质及其制备、检测方法和应用 |
| CN110357824A (zh) * | 2019-06-10 | 2019-10-22 | 中山大学 | [3,5-二取代苯基-1-(1,2,4-三氮唑基)]苯磺酸衍生物及制备方法和应用 |
| WO2022076741A1 (en) * | 2020-10-07 | 2022-04-14 | Reiley Pharmaceuticals, Inc. | Coxib-derived conjugate compounds and methods of use thereof |
| IL305573A (en) | 2021-03-15 | 2023-10-01 | Saul Yedgar | HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES |
| CN118702908B (zh) * | 2024-06-03 | 2025-09-23 | 陕西师范大学 | 含硫聚乙二醇衍生物及其制备方法和在醇羟基选择性氧化中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1128526A (en) * | 1979-10-05 | 1982-07-27 | Cdc Life Sciences Inc. | 3,4-diarylisoxazol-5-acetic acids |
| JP2622887B2 (ja) * | 1988-11-21 | 1997-06-25 | 大鵬薬品工業株式会社 | イソキサゾール誘導体及びその製法 |
| US5310926A (en) * | 1990-01-24 | 1994-05-10 | Taiho Pharmaceutical Co., Limited | Process for producing isoxazole derivatives |
| JPH04134077A (ja) * | 1990-09-21 | 1992-05-07 | Taiho Yakuhin Kogyo Kk | イソオキサゾール化合物 |
| JP2838233B2 (ja) * | 1990-11-08 | 1998-12-16 | 大鵬薬品工業株式会社 | 3,4―ジフエニルイソキサゾール誘導体 |
| EP0633254A1 (en) * | 1991-05-01 | 1995-01-11 | Taiho Pharmaceutical Co., Ltd. | Novel isoxazole derivative and salt thereof |
| JPH06135948A (ja) * | 1992-10-30 | 1994-05-17 | Taiho Yakuhin Kogyo Kk | スチレン誘導体又はその塩 |
| WO1994017059A1 (fr) * | 1993-01-29 | 1994-08-04 | Nippon Soda Co., Ltd. | Derive heterocyclique |
| AU6115794A (en) * | 1993-03-02 | 1994-09-26 | Fujisawa Pharmaceutical Co., Ltd. | Isoxazole derivative |
| DE4314966A1 (de) * | 1993-05-06 | 1994-11-10 | Fahlberg List Pharma Gmbh | 2-Hydroxyphenylsubstituierte Isoxazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel |
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| DK124393D0 (da) * | 1993-11-03 | 1993-11-03 | Lundbeck & Co As H | Compounds |
| GB9324244D0 (en) * | 1993-11-25 | 1994-01-12 | Merck Sharp & Dohme | Therapeutic agents |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
-
1996
- 1996-02-12 BR BR9607035A patent/BR9607035A/pt not_active IP Right Cessation
- 1996-02-12 PL PL96351239A patent/PL185544B1/pl not_active IP Right Cessation
- 1996-02-12 AU AU48671/96A patent/AU699593B2/en not_active Ceased
- 1996-02-12 PL PL96321814A patent/PL185510B1/pl not_active IP Right Cessation
- 1996-02-12 DK DK96904614T patent/DK0809636T3/da active
- 1996-02-12 DE DE69623444T patent/DE69623444T2/de not_active Expired - Lifetime
- 1996-02-12 PT PT96904614T patent/PT809636E/pt unknown
- 1996-02-12 CZ CZ19972546A patent/CZ293211B6/cs not_active IP Right Cessation
- 1996-02-12 RO RO97-01522A patent/RO119946B1/ro unknown
- 1996-02-12 EP EP96904614A patent/EP0809636B1/en not_active Expired - Lifetime
- 1996-02-12 JP JP52505796A patent/JP3267300B2/ja not_active Expired - Fee Related
- 1996-02-12 WO PCT/US1996/001869 patent/WO1996025405A1/en not_active Ceased
- 1996-02-12 DE DE2003199017 patent/DE10399017I1/de active Pending
- 1996-02-12 CA CA002212836A patent/CA2212836C/en not_active Expired - Lifetime
- 1996-02-12 ES ES96904614T patent/ES2183935T3/es not_active Expired - Lifetime
- 1996-02-12 RU RU97115452/04A patent/RU2200158C2/ru not_active IP Right Cessation
- 1996-02-12 NZ NZ302586A patent/NZ302586A/en not_active IP Right Cessation
- 1996-02-12 AT AT96904614T patent/ATE223390T1/de active
- 1996-02-12 CN CN96193240A patent/CN1107058C/zh not_active Expired - Fee Related
- 1996-02-12 DE DE1996623444 patent/DE10399017I2/de active Active
- 1996-08-14 US US08/702,417 patent/US5859257A/en not_active Expired - Lifetime
-
1997
- 1997-02-18 US US08/801,768 patent/US5985902A/en not_active Expired - Lifetime
- 1997-08-11 FI FI973292A patent/FI120736B/fi not_active IP Right Cessation
- 1997-08-12 NO NO19973711A patent/NO312066B1/no not_active IP Right Cessation
-
1999
- 1999-06-21 NZ NZ336369A patent/NZ336369A/en not_active IP Right Cessation
-
2001
- 2001-10-24 JP JP2001326343A patent/JP2002179656A/ja active Pending
-
2003
- 2003-02-28 CN CNB031070426A patent/CN1214790C/zh not_active Expired - Fee Related
- 2003-05-13 NL NL300128C patent/NL300128I2/nl unknown
- 2003-06-04 LU LU91024C patent/LU91024I2/fr unknown
- 2003-07-24 NO NO2003005C patent/NO2003005I2/no unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008001930A1 (en) | 2006-06-28 | 2008-01-03 | Aska Pharmaceutical Co., Ltd. | Pyridylisoxazole derivative |
| JP2010538001A (ja) * | 2007-08-27 | 2010-12-09 | ヘリコン・セラピューティクス・インコーポレーテッド | 治療用イソオキサゾール化合物 |
| JP2012506386A (ja) * | 2008-10-21 | 2012-03-15 | メタボレックス, インコーポレイテッド | アリールgpr120受容体アゴニストおよびその使用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH11503722A (ja) | 炎症の治療のための置換イソオキサゾール | |
| KR100340771B1 (ko) | 염증치료용 치환 이소옥사졸 | |
| JP4049307B2 (ja) | Cox−2阻害剤のプロドラッグとしての置換ベンゼンスルホンアミド誘導体 | |
| JP3490716B2 (ja) | 炎症治療用3,4−置換ピラゾール | |
| US6673818B2 (en) | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | |
| JPH08510736A (ja) | 炎症治療用置換オキサゾリル化合物 | |
| JPH09505830A (ja) | 炎症の治療のための1,3,5−トリ置換ピラゾール化合物 | |
| WO1996036617A1 (en) | Substituted oxazoles for the treatment of inflammation | |
| CA2223091A1 (en) | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | |
| US20020183362A1 (en) | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | |
| TW449587B (en) | Substituted isoxazoles for the treatment of inflammation | |
| US20040092552A1 (en) | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090111 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090111 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100111 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110111 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110111 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120111 Year of fee payment: 10 |
|
| LAPS | Cancellation because of no payment of annual fees |